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 Isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), 
precursors for the biosynthesis of terpenoids, can be formed either by the mevalonate or 
methylerythritol phosphate pathway. The methylerythritol phosphate (MEP) pathway is 
not present in humans, therefore the enzymes of the pathway are potential targets for the 
development of novel antibiotic agents. Five steps, catalyzed by the ispD-H proteins, are 
required for the enzymatic conversion of MEP to IPP and DMAPP. Analogues for MEP, 
aminomethylerythritol phosphate (NMEP), methylerythritol thiophosphate (MESP), and 
thiomethylerythritol phosphate (SMEP) were synthesized and their enzymatic activity for 
conversion to the cyclic intermediates by the consecutive action of three proteins, ispD, 
ispE, and ispF, is examined. The last step of the pathway, catalyzed by the ispH, requires 
elimination of the hydroxyl group from hydroxydimethylallyl diphosphate (HDMAPP), 
the immediate precursor of IPP and DMAPP. Analogues of HDMAPP, 
aminodimethylallyl diphosphate (NDMAPP), and thiodimethylallyl diphosphate 
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Isoprenoid compounds represent one of the most chemically diverse families in 
nature, with more than 55 000 identified specimens to date.1 They exhibit a broad range 
of structural complexity and are involved in a variety of biological processes.  These 
functions include mediation of cell-wall and glycoprotein biosynthesis (dolichol 
diphosphates), electron transport and redox chemistry (ubiquinones), modification of 
tRNA (N6-isopentenyladenine), posttranslational modification of proteins (farnesylated 
proteins), photooxidative protection (carotenoids), contribution to lipid membrane 
structure (cholesterol), antitumor compounds (taxol), as antibiotics (terpentecin), and 
phytoalexins (trichothecin) (Figure 1.1).2 
The structural diversity of isoprenoid compounds is formally derived from the 
branched C5 skeleton of isoprene. Both dimethylallyl diphosphate (DMAPP) and 
isopentyl diphosphate (IPP) correspond to the biological equivalents of isoprene. The 
carbon skeletons of isoprenoid compounds are synthesized by condensing IPP with 
DMAPP (or DMAPP like allylic diphosphates) or condensing two molecules of DMAPP 
(or DMAPP like allylic diphosphates). Isoprenoid molecules are constructed from IPP 





























































These alkylations include “Chain elongation,” 1’-4 coupling between IPP and 
DMAPP to obtain molecules, like geranyl diphosphate; “Branching,” 1’-2 connection of 
two allylic diphosphates, like lavandulol; “Cyclopropanation” - c1’-2-3 connection, to 
form molecules like chrysantamyl diphosphate; Cyclobutanation” - c1’-2-3-2’ 
connection. These possible connections are shown in Figure 1.2.  
The mechanisms for these steps proceed by dissociative electrophilic alkylation. 
The cations generated from DMAPP (or DMAPP like diphosphates) alkylate the double 
bond of IPP or DMAPP. Heterolytic cleavage of the bond between the diphosphate 
moiety and C1 of DMAPP generates an allylic carbocation. The double bond of IPP is 
alkylated by the allylic cation to generate a tertiary cation. An external base removes the 
pro-R proton from the IPP unit to form an E double bond in GPP (Figure 1.3).3 These 
mechanisms are shown on Figure 1.3 and Figure 1.4.  
The mechanism of cyclopropanation, branching, and cyclobutanation can be 
represented in a similar manner. Heterolytic cleavage of the bond between the 
diphosphate group and C1 of DMAPP generates an allylic carbocation. Alkylation of 
allylic cation by the double bond of DMAPP produces a protonated cyclopropane 
intermediate (Figure 1.4).  
The rearrangement of the protonated intermediate gives several final products. 
First, it can be deprotonated to give chrysantamyl diphosphate. Second, it can open and 
either be deprotonated to give lavandulol diphosphate or cyclize to a cyclobutyl structure 























































































Figure 1.4. Mechanism for cyclopropanation, branching, and cyclobutanation. 
 
The biosynthesis of higher order isoprenoids such as geranyl diphosphate, 
farnesyl diphosphate, and geranylgeranyl diphosphate arise from chain elongation 
coupling between IPP and DMAPP (Figure 1.5). These compounds are important 
intermediates for the biosynthesis of other isoprenoids including cyclic compounds. For 
example, cyclization of geranylgeranyl diphosphate (GGPP) to the bicyclic terpene – ent 







































Mevalonate Pathway to IPP and DMAPP 
Isoprenoid biosynthesis depends on the synthesis of IPP and DMAPP. The 
elucidation of the biosynthesis of IPP and DMAPP resulted in the discovery of the 
mevalonate (MVA) pathway in the 1950s.  This work was performed with liver tissues 
and yeast during studies of cholesterol and ergosterol and biosynthesis was later 
confirmed for the biosynthesis of plant sterols and triterpenes. As a result, mevalonate 
was unanimously accepted as the universal isoprenoid precursor in all living organisms, 
despite some contradictory results obtained when working with chloroplasts and some 
bacteria.4 
The MVA pathway begins with a Claisen condensation followed by an aldol 
condensation to yield acetoacetyl CoA and hydroxymethylglutaryl CoA. A NADPH-
dependent reducing enzyme catalyzes the first committed step in the pathway – the 
reduction of hydroxymethylglutaryl CoA to mevalonate. Three successive 
phosphorylations followed by decarboxylation finally yield a five-carbon atom skeleton 
of IPP.  IPP isomerase rearranges IPP to DMAPP (Scheme 1.1). 
It was assumed for several decades that bacteria,5 plants,6 and green algae7 
synthesize IPP and DMAPP from acetyl-CoA according to the well-established MVA 
pathway. However, some discrepancies in the MVA pathway were reported. 14C-labeled 
mevalonate is poorly incorporated into carotenoids from plant chloroplasts;8  mevinolin, a 
potent inhibitor for HMGCoA reductase, had no effect on carotenoid biosynthesis;9 The 
incorporation of 13C-labeled and 14C-labeled acetate into prenyl chains in E.coli resulted 











































Scheme 1.1. Mevalonate (MVA) pathway. 
 
Early on, these contradictory results did not raise concerns about the general idea of 
MVA pathway for biosynthesis of IPP and DMAPP. For example, the negative result 
with mevinolin was attributed to impermeability of the chloroplast membrane.11 
An alternative pathway was discovered during studies of hopane biosynthesis. 
Hopanoids are a group of pentacyclic triterpenes, structurally similar to steroids which 
are synthesized by cyclization of squalene and probably serve a similar physiological role 
(Figure 1.6).4,12  
Hopanoids are usually present in cells in high concentrations. For example, in Z. 
mobilis they reach a maximum of 30 mg/g (dry weight).13 Their availability, chemical 
stability, and ease of isolation made them attractive for biosynthetic studies with 13C 

















Figure 1.6. Hopanoids. 
 
The interpretation of data showed an unexpected labeling pattern that was 
inconsistent with the classical acetate-mevalonate pathway (Figure 1.7). The existence of 
two noninterconvertible acetyl CoA pools was hypothesized. However, these data alone 
were not sufficient to explain the labeling observation. The discovery of the new pathway 
became clear after the incubation experiments of 13C-labeled glucose, which is 
metabolized in Z. mobilius via Entner-Doudoroff route.15  After the assignment of all 
carbon atoms in metabolites derived from IPP and DMAPP, it became evident that there 
is a novel pathway present, which was named the mevalonate-independent, or later, the 
methylerythritol phosphate pathway.16  
 







from [2-13C]acetate from [1-13C]acetate from [2-13C]acetate from [1-13C]acetate
 
Figure 1.7. Results of labeling studies. 
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Methylerythritol Phosphate Pathway to IPP and DMAPP 
 NMR studies14,17 have shown that most eukaryotes and archaebacteria operate 
using a “mevalonate-independent” or methylerythritol phosphate (MEP) pathway 
(Scheme 1.2). The MEP pathway begins with the condensation of glyceraldehyde 
phosphate and pyruvate to form 1-deoxy-D-xylulose-5-phosphate (DXP) catalyzed by 
DXP synthase.  DXP is then rearranged and reduced to methylerythritol phosphate 
(MEP) by MEP synthase. This is the first committed step in the pathway. The pathway 





















































































Scheme 1.2. Methylerythritol Phosphate (MEP) Pathway. 
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 In the second committed step of the MEP pathway, MEP is converted to 4-
diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) by CDP-ME synthase. In the third 
step, CDP-ME is phosphorylated to 2-phospho-4-(cytidine 5′-diphospho)-2-C-methyl-D-
erythritol (CDP-MEP) by CDP-ME kinase. CDP-MEP is then converted into 2-C-methyl-
D-erythritol-2,4-cyclodiphosphate (cMEPP) by cMEPP synthase. A reductive ring 
opening of cMEPP provides 4-hydroxy-dimethylallyl-diphosphate (HDMAPP). IspH 
catalyzes the final step of the MEP pathway – formation of IPP and DMAPP.  
There is only one potent inhibitor reported to date that specifically blocks the 
MEP pathway. Fosmidomycin inhibits the MEP synthase activity with an IC50 value of 
8.2 nM and a Ki value of 38 nM.18 The hydroxamic acid isostere of fosmidomycin and its 
methyl derivative are also potent inhibitors of MEP synthase.19 Some modifications of 
fosmidomycin as FR900098 and 33289 have been reported and now their potency is 
being investigated.20 Animals do not posses the enzymes found in the MEP pathway.21 
Thus, those enzymes are attractive targets for the development of herbicides and 
antimicrobial agents. 
 
Crossover of MVA and  
MEP Pathways 
Utilization of both pathways simultaneously was found only in higher plants and 
some microorganisms.22 Their simultaneous functioning within the same cell raises 
questions of regulation and coordination of pathways. In the pathenogenic bacterium 
Listeria monocytogenes, both pathways are present, so the inhibition of any one of them 
does not interfere with organism survival.23 In Streptomices aeriouvifer and Actinoplanes 
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sp. A40644, isoprenoids are synthesized by MEP in earlier growth stages, and by MVA at 
latter stages.24 It is suggested that in Streptomyces the primary isoprenoid metabolites are 
from MEP, while the secondary ones are from MVA.23  
A different situation is found in plants. In chloroplasts of plant cells, isoprenoids 
are synthesized from MEP, while in cytoplasm, they are from MVA. Therefore, although 
both pathways are present at the same time, they operate in separate compartments.25 
 
Distribution of MEP and  
MVA Pathways 
The nucleic acid sequences of about 150 microbial species afford a relatively 
detailed picture of the occurrence of MVA and MEP pathways.26 All known archaeal 
genomes contain genes are similar to three MVA pathway genes: 3-hydroxy-3-
methylglutaryl-CoA synthase (hmgs), 3-hydroxy-3-methylglutaryl-CoA reductase 
(hmgr), and mevalonate kinase (mk). On the other hand, genes that code for 
phosphomevalonate kinase (Pmk), diphosphomevalonate decarboxylase (Dpmd), and 
isopentenyl diphosphate isomerase (IDI type I) from eukaryotes are not found. Borrelia 
burgdorferi and Staphylococcus aureus carry complete sets of MVA pathway genes, but 
do not have the gene for IDI type I. Instead, they carry a newly discovered gene for a type 
II isopentenyl diphosphate isomerase (IDI type II). The genome of Listeria 
monozytogenes contains complete sets of MVA and MEP pathway genes along with the 
gene for IDI type II. Streptomyces coelicolor has a complete set of MEP pathway genes. 
On the other hand, some Streptomyces sp. possess enzymes of the mevalonate pathway. 
No genes with similarity to those of either the MVA pathway or the MEP pathway were 
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found in Mycoplasma genitalium or Rickettsia provazekii. Some eubacteria with full sets 
of MEP pathway genes, e.g. E. coli, Synechocystis sp., B. subtilis, Deinococcus 
radiodurans, and M. tuberculosis, possess gene orthologs for either IDI type I or II. Since 
IPP and DMAPP can be synthesized independently by the catalytic action of the IspH 
protein, it can be assumed that the isomerases serve as nonessential pathway proteins in 
organisms. The deletion of idiI mutants in E. coli was found to be not lethal.26 
 
DXP Synthase (DXS) 
The initial step in the MEP pathway is the formation of 1-deoxy-D-xylulose 5-
phosphate by the condensation of pyruvate and D-glyceraldehyde 3-phosphate, catalyzed 
by DXP synthase (Scheme 1.2). The dxs gene was first cloned from E. coli. This enzyme 
has a typical thiamine-binding motif and needs both thiamine and a divalent cation such 
as Mg2+ or Mn2+ for activity.27 DXP is a biosynthetic intermediate not only for IPP and 
DMAPP but also for thiamine and pyridoxol. This fact means that DXP synthase is a key 
enzyme not only for the MEP pathway but also for thiamine and pyridoxol biosynthesis.  
Only recently, structures of the Escherichia coli and Deinococcus radiodurans enzymes 
were reported.28 The DXS subunit consists of three domains, each similar to equivalent 
domains of transketolase, which catalyzes a similar reaction. The X-ray structure of DXS 
is shown in Figure 1.8. However, the arrangement of domains is different in the two 
enzymes. Like transketolase, the DXS coenzyme complex is expected to form a covalent 
adduct between thiamine diphosphate and the C2 of pyruvate.29 Unlike transketolase 
where the active site is located at the dimer interface, the active site of DXS is created  
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Figure 1.8. X-ray structure of DXS. 
 
with the cofactor buried within a monomer, placing the thiazolium moiety at the base of a 
polar cavity. The structures required to confirm aspects of specificity for and binding of 
substrate are lacking. 
 
MEP Synthase (IspC) 
Rohmer and coworkers found that 2-C-methylerythritol was incorporated into the 
side chain of ubiquinone in E. coli.30 The studies also showed that MEP is synthesized in 
a single step by rearrangement of DXP followed by reduction of the aldehyde by NADPH 
(Scheme 1.2).31 This is the first committed step in the pathway. The crystal structure of 
MEP synthase from E. coli complexed with NADPH was reported as a homodimer 
(Figure 1.9).32 The monomer structure is composed of three domains: an N-terminal 
NADPH binding domain, a central domain, and a C-terminal α-helical domain. The     
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Figure 1.9. X-ray structure of IspC. 
 
crystal structure indicated that the important amino acid residues for catalysis and DXP 
binding are located in a catalytic pocket in the central domain with N- and C-terminal 
domains protruding into the pocket. The crystal structure also suggested that a loop 
portion between His-209 through Met-214 can be a “hatch” that closes the active site 
when the substrate entered the catalytic pocket. A hydrogen bond between His-209 and 
the phosphate group in DXP could close the hatch to fix the substrate so that the reaction 
proceeds effectively.33,34 Koppish et al. reported that a divalent metal was required for 
activity.35 
The crystal structure with fosmidomycin (inhibitor of MEP synthase) reveals 
hydrogen bonding interactions between the phosphonate group and Ser-186, Ser-222, 




There are two mechanisms proposed for the conversion of DXP to MEP, α-ketol 
(Scheme 1.3) and retroaldol rearrangements (Scheme 1.4).37 The α-ketol mechanism 
involves the deprotonation of the hydroxyl group at C3 of DXP, followed by the 
migration of the phosphate-bearing C2 subunit to afford an aldehyde, which is then 
reduced to form MEP. Examples of reactions proceeding by a 
retroaldolization/aldolization type mechanism instead of α-ketol rearrangement are also 
found in the literature. An example is the reaction catalyzed by the ribulose 5-phosphate 
4-epimerase.38 
In the retroaldol mechanism (Scheme 1.4), a base deprotonates a  hydroxyl group 
at C4, followed by cleavage of the C3-C4 bond to give two species - glycoaldehyde 
phosphate and hydroxyacetone enolate. Subsequent aldolization gives identical aldehyde 
intermediate generated by an α-ketol rearrangement, followed by NADPH reduction to 
give MEP. Fox et al. prepared a set of fluoro DXP analogues as substrates/inhibitors for 
























































X = H+ or a divalent metal
  
Scheme 1.3. Possible mechanism for MEP synthase - α-ketol rearrangement. 
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Scheme 1.4. Possible mechanism for MEP synthase - retroaldol rearrangement. 
 
sequentially replaced by a fluorine atom to give CF-DXP, CF2-DXP, and CF3-DXP 
(Figure 1.10). CF2-DXP and CF3-DXP were modest inhibitors of MEP synthase with 
IC50 values of 2.0 and 3.4 mM, respectively. CF-DXP was a good substrate (kcat = 38 s-1, 
Km = 227 µM) with a turnover rate similar to that of the natural substrate. These results 
support a retroaldol mechanism rather than an α-ketol rearrangement for the enzyme-
catalyzed conversion of DXP to MEP. 
Additionally, Walker et al. synthesized and evaluated a series of DXP analogues 
as inhibitors of E. coli MEP synthase.39 The methyl group in DXP was replaced by 
hydroxyl, hydroxylamino, methoxy, and amino moieties, respectively.  
 
 
Figure 1.10. Fluoro analogues of DXP. 
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Also, the acetyl moiety in DXP was replaced by hydroxymethyl and aminomethyl 
groups (Figure 1.11). These compounds were designed to coordinate to the active site 
divalent metal in MEP synthase. The carboxylate, methyl ester, amide, and alcohol 
analogues were inhibitors with IC50's ranging from 0.25 to 1.0 mM. The hydroxamic acid 
and amino analogues did not inhibit the enzyme. These results show that the MEP 
synthase has strict requirements for inhibitors or substrates. The most potent members of 
the group closely approximated the size of DXP and contained functional groups that 
could bind to the divalent metal in the active site. Changes that compromise either of 
these two features result in a substantial decrease of potency. 
 
CDP-ME Synthase (IspD) 
The IspD gene product converts MEP into 4-(cytidine 5’-diphospho)-2-C-methyl-D-
















































Figure 1.11. Analogues of DXP synthase.40 
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Noel and coworkers have reported three-dimensional dimer structures of CDP-
ME synthase in the apo form and the form bound to CTP-Mg2+ or CDP-ME-Mg2+.41 The 
X-ray structure is shown in Figure 1.12. 
 The subunit is a single domain α/β structure constructed around a seven-stranded 
twisted β-sheet into which is inserted an extended “β-arm.” Two arms form a dimer 
interface that involves numerous hydrogen bonds and salt bridges. Interactions of the 
protein with the cytosine moiety of CTP include coordination of nitrogen with Ser-88, 
hydrogen bonds between the carbonyl group and Ala-14, and Ala-15 backbone amides. 
Arg-20 interacts with the α- and γ-phosphates, Lys-27 plays an essential role in catalysis, 
and Lys-213 could act as an electrostatic guide for the phosphate function of MEP prior 
to nucleophilic attack on CTP. The product of catalysis is stabilized by interaction with a 
side chain of Thr-165. Several bacteria were found to have a bifunctional fusion genes 
consisting of IspD and IspF domains. In Agrobacterium tumefaciens, the ispD and ispF 
genes are fused to encode a bifunctional enzyme that catalyzes the first (synthesis of 4- 
 
Figure 1.12. X-ray structure of IspD. 
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diphosphocytidyl-2-C-methyl-D-erythritol) and third (synthesis of 2-C-methyl-D-
erythritol 2,4-cyclodiphosphate) steps. Lherbet et al.42 showed with sedimentation 
velocity experiments that the bifunctional IspDF and IspE proteins associate in solution. 
However, a time course experiment indicated that the intermediates are not transferred 
from the IspD active site in IspDF to the active site of IspE or from the active site in IspE 
to the active site of the IspF module of IspDF. The CDP-ME was also synthesized 
independently by Koppisch et al.43 by coupling of free phosphoacid of MEP with cytidine 
5’-monophosphate using a protocol originally developed for synthesis of base-sensitive 
nucleoside diphosphate sugars.44 
 
CDP-ME Kinase (IspE) 
The IspE gene product converts CDP-ME into 2-phospho-4-(cytidine 5’-
diphospho)-2-C-methyl-D-erythritol (CDP-MEP) in the presence of ATP (Scheme 1.2).45 
The dimer structure of this enzyme in its apo form recently was reported without bound 
substrates.46 It was proposed that Asn-58 and Lys-83 are involved in binding ATP and 
that Ser-95 and Asp-125 coordinate to Mg2+.  It was suggested that the Asp-125 oxygen, 
activated by Lys-8, eliminates the proton from the hydroxyl group at C2 position of CDP-
ME.   The X-ray structure is shown on Figure 1.13.  
The enzyme displays the characteristics of a GHMP kinase α/β fold, with cofactor 
and substrate-binding domains. The Lys-10 and Asp-141 pair forms hydrogen bonds with 
substrate and polarizes the hydroxyl group to facilitate proton removal by Asp-141. 
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Figure 1.13. X-ray structure of IspE. 
 
The γ-phosphate of the cofactor is transferred to CDP-ME to produce 4-
diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate (CDP-MEP) and ADP. There is no 
evidence for divalent metal ion binding to the cofactor, and the cofactor purine forms 
hydrogen-bonding interactions that stabilize the less common syn orientation of the base 
with respect to the glycosidic bond.47 
 
cMEPP Synthase (IspF)  
The IspF gene product converts CDP-MEP into 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate (cMEPP) (Scheme 1.2). The formation of cMEPP was concomitant 
with elimination of CMP from CDP-MEP. The X-ray structure is shown in Figure 1.14. 
The crystal structure of cMEPP synthase from E. coli was reported independently by 
three groups.48,49,50 The crystal structure presents a compact homotrimer in the 
asymmetric unit.  The IspF subunit is a small single α/β domain and consists of a four-
stranded mixed β-sheet on one side with three α helices on the other. Two metal 
coordination sites were reported in the structure. 
 22 
 
Figure 1.14. X-ray structure of IspF. 
 
A Zn2+ site positions the phosphate group and facilitates the nucleophilic attack. 
A second metal Mn2+ coordinates the diphosphate group. In the site, Lys-130 forms a salt 
bridge with Asp-95, Ala-131 binds the cytidyl group, and Thr-133 forms hydrogen bonds 
with the phosphate of CDP or CMP upon release. The enzyme requires both cations for 
catalysis, one of which (Zn2+) is always present in the active site.  
 
IspG and IspH Proteins 
The two least studied enzymes in the MEP pathway, IspG and IspH, are described 
more closely in Chapter 2. cMEPP  undergoes reduction and elimination to 4-hydroxy-3-
methyl-2-(E)-butenyl-4-diphosphate (HDMAPP), followed by reduction to IPP and 
DMAPP (Scheme 1.2). An amino acid sequence comparison of the E. coli IspG protein 
with the orthologs from M. tuberculosis and P. falciparum shows a high degree of 
homology among the sequences.51 These genes specify a cluster of three absolutely 
conserved cysteines52 typical for iron–sulfur proteins such as the S-adenosyl methionine 
 23 
dependent radical enzyme family. Optical spectra showed a shallow absorption maximum 
at about 410 nm which has been interpreted as evidence for an iron–sulfur cluster. The 
conserved cysteine residues are assumed to be involved in the binding of that cluster. The 
extraordinary sensitivity of the enzyme against molecular oxygen is well in line with the 
hypothesis that the iron–sulfur cluster is essential for the reaction mechanism. Since IspH 
protein as well as IspG protein contains three conserved cysteine residues, they are 
believed to be involved in catalysis or binding. The replacement of any of the cysteine 
residues reduced the catalytic activity of the IspH protein by a factor of more than 
70,000. In order to eliminate the OH group, the formation of reactive intermediates, in 
which the symbol * is a reference to the unknown number of electrons (Scheme 1.5). The 
reaction could proceed via an anionic, radical, or a cationic allyl system. Both IPP and 
DMAPP can be obtained by the transfer of H+, H• or H– to either the C2 or C4 position of 
the hypothetical intermediate. 
 
Overview of Dissertation 
Chapter 2 will present the synthesis of HDMAPP analogues, where the hydroxy 
group is substituted by amino and thio groups. Chapter 3 will present the synthesis of 
analogues for the MEP, where the primary hydroxy group is displaced with the amino 









Scheme 1.5. A generalized structure for the hypothetical intermediate(s) at the branching 
point of the IspH-mediated reaction. 
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displaced by thiol. The LCMS and radioactive isotope labeling experiments are 





1. Thulasiram, H. V.; Erickson, H. K.; Poulter, C. D. Science, 2007, 316, 73-75. 
2. Cane, D. E. Comprehensive Natural Products Chemistry; Barton D., Nakanishi, K., 
Meth-Cohn, O., Ed. Elsevier, Oxford, UK, 1999, vol. 2, 1-11. 
3. Dolence, J. M. Poulter, C. D. Comprehensive Natural Products Chemistry; O. Meth-
Cohn, Ed. Elsevier, Oxford, UK, 1999, vol. 5, 18473–18500. 
4. .Rohmer, M.  Comprehensive Natural Products Chemistry;  Barton D., Nakanishi, K., 
Meth-Cohn, O., Ed. Elsevier, Oxford, UK, 1999, vol. 2, 45-67. 
5. Rohmer, M.; Sutter, B.; Sahm, H. J. Chem. Commun., 1989, 1471-1472. 
6. Eisenreich, W.; Menhard, B.; Hylands, P.; Zenk, M.; Bacher, A. Proc. Natl. Acad. Sci. 
USA, 1996, 93, 6431-6436. 
7. Schwender, J.; Seeman, M.; Lichtenthaler, H.; Rohmer, M. Biochem. J., 1996, 316, 73-
80. 
8. Banthorpe, D. V.; Charlwood, B. V.; Francis, M. J. O. Chem. Rev., 1972, 72, 115–155. 
9. Bach, T. J.; Motel, A.; Weber, T. Rec. Adv. Phytochem., 1990, 24, 1–82. 
10. Rohmer, M. Pure Appl. Chem., 2003, 75, 375-387. 
11. Bach, T.; Motel, A.; Weber, T. Rec. Adv. Phytochem., 1990, 24, 1-82. 
12. Rohmer, M.; Bouvier, P.; Ourisson, G. Proc. Natl. Acad. Sci. USA, 1979, 76, 847-
851. 
13. Rohmer, M.; Bouvier-Nave, P.; Ourisson, G. J. Gen. Microbiol., 1984, 130, 1137-
1150.  
14. Flesch, G.; Rohmer, M. Eur. J. Biochem.,  1988, 175, 405-411. 
15. Conway T. FEMS Microbiol Rev., 1992, 1, 1–27. 




17. Eisenreich, W.; Schwarz, M.; Cartayrade, A.; Arigoni, D.; Zenk, M.; Bacher, A. 
Chem. Biol., 1998, 5, 221-233. 
18. Kuzuyama, T.; Shimizu, T.; Takahashi, S.; Seto, H. Tetrahedron Lett., 1998, 39, 
7913-7916. 
19. Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.; Willem, A.; Bach, 
T. J.; Rohmer, M. Biochem. J., 2005, 386, 127-135. 
20. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; 
Türbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E.  Science, 
1999, 285, 1573 – 1576. 
21. Lange, B.; Rujan, T.; Martin, W.; Croteau, R. Proc. Natl. Acad. Sci. USA, 2000, 97, 
13172-13177. 
22. Kuzuyama, T.; Takagi, M.; Takahashi, S.; Seto, H. J. Bacteriol., 2000, 182, 891-897. 
23. Hamano, Y.; Dairi, T.; Yamamoto, M.; Kuzuyama, T.; Itoh, N.; Seto, H. Biosci. 
Biotechnol. Biochem., 2002, 66, 808-816. 
24. Seto, H.; Orihara, N.; Furihata, K. Tetrahedron Lett., 1998, 39, 9427-9500. 
25. Schwender, J.; Zeidler, J.; Groner, R.; Muller, C.; Focke, M.; Braun, S.; 
Lichtenthaler, F.; Lichtenthaler, H. FEBS Lett., 1997, 414, 129-134. 
26. Eisenreich, W.; Bacher, A.; Arigoni, D.; Rohdich, F. Cell. Mol. Life Sci., 2004, 61, 
1401–1426. 
27. Kuzuyama, T.; Seto H. Nat. Prod. Rep., 2003, 20, 171–183. 
28. Xiang, S.; Usunow, G.; Lange, G.; Busch, M.; Tong, L. J. Biol. Chem., 2007, 282, 
2676–2682. 
29. Fiedler, E.; Thorell, S.; Sandalova, T.; Golbik, R.; Konig, S.; Schneider, G. Proc. 
Natl. Acad. Sci. USA, 2002, 99, 591–595. 
30. Duvold, T.; Cali, P.; Bravo, J.; Rohmer, M. Tetrahedron Lett., 1997, 38, 6181-6184. 
31. Takahashi, S.; Kuzuyama, T.; Watanabe, H.; Seto, H. Proc. Natl. Acad. Sci. USA, 
1998, 95, 9879-9884. 
32. Estevez, J. M.; Cantero, A.; Reindl, A.; Reichler, S.; Leon, P. J. Biol. Chem., 2001, 
276, 22901–22909. 




34. Reuter, K.; Sanderbrand, S.; Jomaa, H.; Wiesner, J.; Steinbrecher, I.; Beck, E.; Hintz, 
M.; Klebe G.; Stubbs, M. T. J. Biol. Chem., 2002, 277, 5378-5384. 
35. Koppisch, A.; Fox, D.; Blagg, B.; Poulter, C. Biochemistry, 2002, 41, 236-243. 
36. Koppisch, A. T.; Blagg, B. S. J.; Poulter, C. D. Org. Lett., 2000, 2, 315-317. 
37. Fox, D. T.; Poulter, C. D. J. Org. Chem., 2005, 70, 1978–1985. 
38. Lee, L. V.; Vu, M. V.; Cleland, W. W. Biochemistry, 2000, 39, 4808–4820. 
39. Walker, J. R.; Poulter, C. D.  J. Org. Chem., 2005, 70, 9955 -9959.  
40. Kuzuyama, T.; Takagi, M.; Kaneda, K.; Dairi T.; Seto, H. Tetrahedron Lett., 2000, 
41, 703-706. 
41. Richard, S. B.; Bowman, M. E.; Kwiatkowski, W.; Kang, I.; Chow, C.; Lillo, A. M.; 
Cane, D. E.; Noel, J. P. Nature Struc. Biol., 2001, 8, 641-648. 
42. Lherbet, C.; Pojer, F.; Richard, S. B.; Noel, J. P.; Poulter, C. D. Biochemisry, 2006, 
45, 3548-3553. 
43. Koppisch, A. T.; Poulter, C. D. J. Org. Chem., 2002, 67, 5416-5418. 
44. Marlow, A. L.; Kiessling, L. L. Org. Lett., 2001, 3, 2517-2519. 
45. Kuzuyama, T.; Takagi, M.; Kaneda, K.; Dairi T.; Seto, H. Tetrahedron Lett., 2002, 
41, 2925-2928. 
46. Wada, T.; Kuzuyama, T.; Satoh, S.; Kuramitsu, S.; Yokoyama, S.; Unzai, S.; Tame, J. 
R,; Park, S. Y.; J. Biol. Chem., 2003, 278, 30022–30027. 
47. Hunter, W. N. J. Biol. Chem., 2007, 282, 21573–21577. 
48. Richard, S.; Ferrer, J.-L.; Bowman, M.; Lillo, A.; Tetzlaff, C.; Cane, D.; Noel, J. J. 
Biol. Chem., 2002, 277, 8667-8672. 
49. Kemp, L.; Bond, C.; Hunter, W. Proc. Natl. Acad. Sci. USA, 2002, 99, 6591-6596. 
50. Steinbacher, S.; Kaiser, J.; Wungsintaweekul, J.; Hecht, S.; Eisenreich, W.; Gerhardt, 
S.; Bacher A.; Rohdich, F. J. Mol. Biol., 2002, 316, 79-88. 
51. Laupitz, R.; Hecht, S.; Amslinger, S.; Zepeck, F.; Kaiser, J.; Richter, G.; Schramek, 
N.; Steinbacher, S.; Huber, R.; Arigoni, D.; Bacher, A.; Eisenreich, W.; Rohdich, F. Eur. 
J. Biochem., 2004, 271, 2658–2669. 
52. Hecht, S.; Eisenreich, W.; Adam, P.; Amslinger, S.; Kis, K.; Bacher, A.; Arigoni, D.; 













The MEP pathway (Scheme 2.1) begins with the condensation of glyceraldehyde 
phosphate and pyruvate to form 1-deoxy-D-xylulose-5-phosphate (DXP) catalyzed by 
DXP synthase.  DXP is then rearranged and reduced by MEP synthase to produce 
methylerythritol phosphate (MEP). MEP is converted into methylerythritol 
cyclodiphosphate (cMEPP) by the consecutive actions of three enzymes: CDPME 
synthase, CDPME kinase, cMEPP synthase. A reductive ring opening of cMEPP 
provides hydroxydimethylallyl diphosphate (HDMAPP). The IspH catalyzes the final 
step of the MEP pathway – formation of IPP and DMAPP. It is interesting to note that in 
contrast to the mevalonate (MVA) pathway, organisms utilizing the MEP pathway do not 
require IPP isomerase activity, although the enzyme is found in most of these  organisms 
(Scheme 2.1).1  
This chapter is dedicated to studies of the last steps of the MEP pathway, 
reactions catalyzed by IspG and IspH. Our goal was to prepare analogues for 4-




















































































Scheme 2.1. Methylerythritol Phosphate (MEP) Pathway. 
 
Additionally, we are interested to see if these analogues will be product inhibitors 
for IspG, since both proteins are similar to some extent.  Overall, the reactions catalyzed 
by IspG and IspH involve elimination and reduction. The nucleotide sequences of the 
genes that encode the proteins have conserved cysteine residues in a pattern consistent 
with formation of a Fe-S cluster.2 This observation is important, since the enzymes are 
oxygen sensitive and require inert atmosphere for their operation. Both proteins have 
three conserved cysteines which form an Fe-S cluster characterized by UV-vis absorption 
with a maximum at 410 nm.3 In the case of the IspG, this cluster was detected by 
Mössbauer spectroscopy, and in case of the IspH enzyme the same cluster was identified 
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by EPR spectroscopy.4 The Fe-S cluster could play a role as a Lewis acid or as a reducing 
agent involved in 1e- transfer.  
The flavodoxin encoding gene fldA is essential for the survival of E. coli.3 It was 
proposed to be involved, along with NADPH, in the reduction of the oxidized [4Fe-4S]2+ 
cluster to the reduced [4Fe-4S]1+ state in IspG and IspH.5 Rohdich et al. discovered that 
40 µM flavodoxin and 12 µM flavodoxin reductase were required for maximum activity 
of IspH expressed from E. coli. Among the total of four cysteines, IspH has three 
absolutely conserved cysteine residues at positions 12, 96, and 197. Replacement of any 
of the conserved cysteines reduced the catalytic activity by a factor of more than 70,000.6  
 
IspG Protein 
Rohmer and coworkers7 reported that cMEPP was a substrate for the IspG 
enzyme. They engineered E. coli cells with deleted dxr and overexpressed IspG genes. 
After incubation of these cells with tritium labeled ME, accumulation of radiolabeled 
HDMAPP was observed, which suggested that cMEPP was a substrate of IspG.  
Incubation of 14C-labeled cMEPP with a crude lysate from E. coli cells with exhanced 
loads of the IspG enzyme led to formation of only one radioactive molecule - 4-
hydroxydimethyallyl alcohol, which was a hydrolysis product of HDMAPP by 
phosphatases. An incubation of cMEPP in the presence of phosphatase inhibitors gave 
HDMAPP, which was compared with chemically synthesized HDMAPP and was 
accepted as the reaction product of the IspG catalyzed reaction.8 HDMAPP was also 
synthesized independently by Fox et al.9 It was also shown by Kollas et al.10 that the 
IspG converts cMEPP to HDMAPP without the need for any additional protein factors by 
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using dithionite as an artificial electron donor. As it was mentioned earlier, the reaction 
catalyzed by the IspG formally involve a two-electron reduction that requires cleavage of 
two carbon-oxygen bonds. It was shown in deuterium labeling studies with E. coli that all 
the C-H bonds of the cMEPP are conserved in IPP and DMAPP.11,12 Two mechanisms 
were proposed to account for these observations (Scheme 2.2 and Scheme 2.3).13  
A 2e- transfer mechanism is presented in Scheme 2.2. In the first step, NADP+ 
oxidizes the primary alcohol to an aldehyde. In the second step, a thiolate displaces the 
diphosphate at C3, leading to a covalent complex between the Fe-S cluster and the 
substrate. In the next step, a disulfide bond is formed with concomitant cleavage of the 
thioether to give an enolate. The enolate is converted to its aldehyde form upon 
protonation of the β hydroxy group followed by displacement of a water molecule. The 
alcohol moiety is restored by reduction with NADPH in the last step to produce 
HDMAPP. An alternative 1e- transfer mechanism is shown in Scheme 2.3. The thiyl 
radical derived from the third conserved cysteine residue removes a hydrogen atom from 
C4 of cMEPP to give an intermediate that is predisposed for diphosphate elimination.  
In the following step, formation of the aldehyde is accompanied by elimination of 
the diphosphate leading to the formation of a tertiary radical. Transfer of one electron 
from a thiol generates a disulfide, and leads to an enolate, which in turn loses water to 
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A similar approach to the described for the IspG studies was used to investigate 
the IspH gene product. Jomaa and coworkers engineered E. coli strain which contained 
the three genes required to convert mevalonate to IPP and deleted IspH gene.14 This 
deletion was lethal. However, the strain could be rescued by addition of mevalonate to 
the medium. Under these conditions, formation of 4-hydroxydimethylallyl diphosphate 
was detected by spectroscopic methods. The role of IspG and IspH was determined by 
incorporation of [U-13C6]DX in E. coli strain with overexpressed enzymes of the MEP 
pathway, followed by analysis of the accumulated metabolites by 13C NMR of the crude 
cell free extracts. Overexpression of IspDEF genes resulted in the accumulation of 
cMEPP product. Additional expression of IspG led to the formation of HDMAPP, while 
expression of IspG and IspH gave IPP and DMAPP in a 5:1 ratio.15 Thus, cMEPP and 
HDMAPP are substrates for IspG and IspH, respectively. 
Recombinant IspH from the thermophilic eubacterium Aquifex aeolicus was 
purified by Jomaa and coworkers.16 The researchers developed a spectrophotometric 
assay to determine the steady-state kinetic parameters of IspH. A maximal specific 
activity of 6.6 ± 0.3 µmol min−1mg−1 protein was determined at pH 7.5 and 60 °C. kcat for 
the IspH was 3.7 ± 0.2 s−1 and the Km value for HDMAPP was 590 ± 60 µM.  
 IspH and IspG proteins contain three conserved cysteine residues, typical of 
protein with an Fe-S cluster, believed to be involved in catalysis or binding.15  The final 
step of biosynthesis of IPP and DMAPP in the MEP pathway requires replacement of a 
hydroxy group by a hydrogen atom. There are two possible mechanisms for this 
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Scheme 2.5. Hypothetical protonation mechanism for the IspH reaction. 
 
by Rohdich et al. involves elimination of the hydroxyl group to generate an allylic cation, 
which is then reduced to an allylic anion and protonated either at carbon C2 or C4 to give 
IPP or DMAPP, respectively (Scheme 2.4).17 Although it was shown that the transferred 
hydrogen is most likely a proton by overall six-fold deuterium discrimination in favor of 
1H in 90% heavy water with IspH from E. coli,18 the reaction might proceed through 
protonation of C4 hydroxyl group with subsequent generation of a tertiary carbocation, 
followed by hydride transfer from NADPH (Scheme 2.5). 
   
Rationale 
We proposed two substrate analogues to test these proposed mechanisms. This 
chapter describes the synthesis and enzymatic activity evaluation of substrate analogues: 
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aminodimethylallyl diphosphate (NDMAPP) and thiodimethylallyl diphosphate 
(SDMAPP) for hydroxydimethylallyl diphosphate (HDMAPP) (Figure 2.1).  
Our intent was to demonstrate how changes in the natural substrate affect the 
enzymatic conversion of the alternative substrates to the final products in the MEP 
pathway, IPP and DMAPP by IspH. We were also interested in the activity of the above-
mentioned molecules with IspG to see if they could serve as product inhibitors. 
NDMAPP can be active as a free amine in the mechanism, where Fe2+ from the iron- 
sulfur cluster acts as a Lewis acid and a radical is formed (Scheme 2.6). Additional 
electron transfer generates an anion which is protonated to give either IPP or DMAPP. 
From another mechanism, the NDMAPP amino group can be protonated by acid, 
followed by ammonia cleavage (Scheme 2.6). NH3+ surrogates for OH2+, but it is a much 
poorer leaving group which may result in no or slow cleavage. SDMAPP can be active by 
slowing down the elimination step in the mechanism, where Fe2+ from the Fe-S cluster 
































































Scheme 2.6. Two hypothetical mechanisms for NDMAPP. 
 
anion which is protonated to give either IPP or DMAPP. However, in the other 
mechanism, the protonation mechanism, SDMAPP will not be active (Scheme 2.7). Also, 
SDMAPP could inhibit the IspH by disrupting the iron-sulfur cluster (Scheme 2.8). The 
potential activity of the proposed analogues is shown in Table 2.1. NDMAPP is expected 
to be less active compared to HDMAPP in both mechanisms. On the other hand, the 
sulfur analogue should be more active than HDMAPP in the radical mechanism since the 
thiol group is a better ligand for Fe2+ than the hydroxyl group. However, the sulfur can 
not be protonated and will be less reactive in the protonation mechanism. Thus, these two 
analogues will help to distinguish the two mechanisms. Therefore, NDMAPP and 
SDMAPP could be potent inhibitors which would interact with the [4Fe-4S] cluster. Here 
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Scheme 2.8. Disruption of Fe-S cluster. 
 
Table 2.1. The potential activity of NDMAPP and SDMAPP. 




C-N less active less active 
C-O active active 
C-S more active less active 
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Synthesis of 4-Aminodimethylallyl Diphosphate 
The synthesis of the amino analogue NDMAPP begins with the one-pot oxidative 
cleavage-Wittig sequence, which is a convenient way to prepare α,β-unsaturated esters.19 
Diethyl tartrate (1) is oxidized with NaIO4 on silica gel (10% by weight)20 to generate an 
aldehyde, which then reacts with the 2-(triphenylphosphoranylidene) ylid by Wittig 
reaction.21 The resulting α,β-unsaturated aldehyde 2 was reduced with NaBH4 without 
purification to give alcohol 3 in 84% in two steps. Allylic alcohol 3 was converted into 
phthalimide 4 using the Mitsunobu procedure22 (Scheme 2.9).  However, reduction of the 
phthalimide with NaBH4, followed by acetic acid gave amine 5 in a low yield.23 The 
stereochemistry of the double bond in phthalimide 4 was assigned by a NOESY 
experiment. The 2D NOESY spectrum of 4 showed a crosspeak between the olefinic 
proton at 5.64 ppm and the methylene protons at 4.31 ppm adjacent to the phthalimide 
moiety (Figure 2.2). This proved the expected E geometry of the double bond from the 
Wittig reaction. Alcohol 3 was protected with a TBDMS group and the resulting ester 6 
was reduced with DIBALH to give alcohol 7, which was then protected with a THP 
group to give 8. The TBDMS group was removed with the Et3N-3HF complex and 
hydroxy group of alcohol 9 was displaced by phthalimide under Mitsunobu conditions to 
give 10 (Scheme 2.10).24 The amino group of 10 was unmasked with hydrazine, and the 
amine 11 was protected with Fmoc-OSu to give compound 12 (Scheme 2.11).25 We 
chose to use this protecting group so the last deprotection step could be performed under 
basic conditions in order to preserve a diphosphate moiety of NDMAPP. The THP group 




















































Scheme 2.9. Formation of amino ester 5.  
 
displacement methodology developed by Davisson et al. where allylic alcohol 13 was 
converted into allylic chloride 14 and then treated with tris(tetrabutylammonium) 
hydrogen diphosphate, to obtain diphosphate NDMAPP (15).26 This method has the 
advantage that only one phosphate-containing compound is produced. Since the 
diphosphate salt is very basic, we thought that the Fmoc group might also be removed 
during phosphorylation to give NDMAPP (Scheme 2.12). However, the outcome was 
almost complete rearrangement of the starting material to alcohol 17 (Scheme 2.13). 
Under these conditions, we have two competitive reactions. The first reaction is a 
displacement of the chloride by inorganic diphosphate (path B), and the second is Fmoc 




                                                                        
                                                                       



















































































































Scheme 2.13. Rearrangement under basic conditions. 
 
Fmoc deprotection is faster, followed by aziridine formation (Scheme 2.13). The 
aziridine 16 opening produces the tertiary alcohol 17. 
We then turned to the Cramer procedure.27 The disadvantage of this method is 
formation of a mixture phosphates, mainly mono and diphosphates. We first tried the 
Danilov modification of the Cramer procedure using bis(tetrabutylammonium) phosphate 
and CCl3CN (Scheme 2.14).28 However, formation of the tertiary alcohol 17 was again 
observed. We then tried the original Cramer reaction modified by Keller and Thompson, 
using TEAP (bis(trimethyl ammonium) phosphate) solution and CCl3CN.29 Use of the 
TEAP eliminated the need for an ion-exchange step. The product is purified by 
chromatography on silica gel with elution by iPrOH/H2O/NH4OH (Scheme 2.15).  
The Fmoc group survived the purification step on silica using 
iPrOH/H2O/NH4OH solvent mixture with pH = 12, and the Fmoc protected diphosphate 
18 was obtained. The Fmoc group was removed with piperidine and NDMAPP (15) was 
obtained after purification on silica gel.25 
 44 
 
Scheme 2.14. The Danilov modification. 
 
 
Scheme 2.15. Formation of diphosphate 15.  
 
Enzymatic Evaluation of 4-Aminodimethylallyl Diphosphate 
NDMAPP was examined as an inhibitor of IspG and IspH by Dr. Seemann in the 
laboratory of Professor Michel Rohmer at the University of Louis Pasteur, Institut de 
Chimie, Strasbourg, France. NDMAPP did not inhibit IspG at concentrations 10 µM, 100 
µM and 1 mM. The experimental results with IspH are shown in Table 2.2. The IC50 
value 0.45 µM was determined using GraFitTM software (see Figure 2.3). At this point, 
we cannot determine the mode of action of this analogue. It will be important to see if 
this substrate is a reversible or a time-dependent irreversible inhibitor of IspH. 
The NDMAPP analogue was also tested against type I and II IDI isomerase 
enzymes. The radioactive assay showed no inhibition activity of NDMAPP against IDI II. 


















0,000 0,1446442 14,17 100,000 - 
0,100 0,1214711 11,90 83,979 -7,000 
0,500 0,0708923 6,94 49,012 -6,301 
0,750 0,0541032 5,30 37,404 -6,125 
1,000 0,0412627 4,04 28,527 -6,000 
1,500 0,0318190 3,12 21,998 -5,824 
5,000 0,0119782 1,17 8,281 -5,301 
10,000 0,0062211 0,61 4,301 -5,000 
 
[NDMAPP]


















Parameter Value Std. Error
Y Range 13.9193 0.2461
IC 50 0.4521 0.0176
Slope factor 1.1223 0.0494
Background 0.2191 0.1673
 




Table 2.3. IC50 determination for the NDMAPP analogue with IDI type I. 
Radioactivity Conc. Of 
NDMAPP trial 1 trial 2 
Average Without 
background 
0 823 1027 925 846 
5 703 753 728 649 
10 656 624 640 561 
20 478 476 477 398 
40 403 329 366 287 
80 257 257 257 178 
150 172 168 170 91 
280 118 114 116 37 
No enzyme 79 79   
1/2 buffer 18499 18499   
 
NDMAPP (uM)








Parameter Value Std. Error
Y Range 894.5310 33.3710
IC 50 21.8322 2.1627
Slope factor 0.8712 0.0610
Background -48.0494 28.6495
 
Figure 2.4. IC50 determination for the NDMAPP analogue with IDI type I. 
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Synthesis of 4-Thiodimethylallyl Diphosphate 
The first step in the synthesis of SDMAPP is shown in Scheme 2.16. The hydroxy 
group of alcohol 9 was esterified to give thioacetate 19. Initially, we tried a Mitsunobu 
displacement with thioacetic acid.30 However, the reaction was not reproducible, and the 
yields varied from 25 to 75%. We found that generally, a better yield was obtained when 
thioacetic acid added dropwise to the solution of the PPh3, DIAD, and corresponding 
alcohol. The thioacetate 19 was prepared by conversion of alcohol 9 into corresponding 
allylic chloride 20,31 followed by displacement of chloride with potassium thioacetate to 
give 19 (Scheme 2.16). The acetate group of 19 was removed with CH3ONa at -40 oC 
(Scheme 2.17). The free thiol group was susceptible to oxidation to form a symmetric 
disulfide in SDMAPP and the intermediates leading to the analogue. When left 
unprotected under mild basic conditions (pH = 7.2), 20% conversion of SDMAPP to 
symmetric disulfide is observed within 1 hour. We chose 2,2’-pyridyl disulfide, which 
can be easily removed in the presence of diphosphate in aqueous media immediately 
before SDMAPP is used in experiments. This reagent is widely used to protect cysteine 
residues in peptide synthesis.32  
 
 





Scheme 2.17. Synthesis of SDMAPP.   
 
The mixed pyridyl disulfide is stable to acid/base conditions, and only sensitive to 
reducing agents. Therefore, the liberated thiol of 19 was treated with 2,2’-pyridyl 
disulfide to give mixed 2-pyridyl disulfide 21. The THP group was then removed to give 
alcohol 22. We tried to introduce the diphosphate using the procedure of Davisson et al.26 
however, the allylic chloride could not be prepared from alcohol 22. Instead, the alcohol 
22 was phosphorylated to give disulfide 23 using the Cramer procedure.29 To prevent 
formation of symmetric disulfide, the SDMAPP is stored as asymmetric disulfide 23 at -
80 oC until needed (Scheme 2.17). The disulfide 23 is treated with DTT for 1 hour to 
give the free thiol SDMAPP (24) in 90% yield. This reaction can be performed directly in 
the assay buffer, since DTT is usually added to it to preserve a protein. 
In summary, the synthesis of NDMAPP and SDMAPP analogues of HDMAPP 
were achieved. The NDMAPP was found to be inactive against IspG and IDI II protein. It 





will be evaluated as an inhibitor or substrate of IspG and IspH by our coworkers in 




NMR spectra were recorded on a Varian Unity Inova NMR 300 MHz FTNMR 
interfaced to a Sun Sparcstation 5 computer at 300 MHz (1H NMR) and 75 MHz (13C 
NMR).  All chemical shifts are reported in parts per million (ppm) and coupling constants 
(J) in hertz (Hz).  1H chemical shifts are referenced relative to the TMS peak at δ 0.0 ppm 
or to the peak of CD2Cl2 at 5.32 ppm.  The 13C chemical shifts are referenced relative to 
CDCl3 at δ 77.0 ppm (center peak), the peak of CD2Cl2 at 54 ppm (center peak), and for 
D2O to MeOH at 49 ppm. 31P chemical shifts are referenced relative to the peak of H3PO4 
in D2O at δ 0 ppm. 
All commercial reagents were ACS reagent grade and were used without further 
purification. In general all solvents, reagents, and deuterated solvents were purchased 
from Fisher Chemicals, Acros, and Aldrich. Methylene chloride and ethanol were 
distilled from CaH2 prior to use. All other reagents were of commercial quality from 
freshly opened containers. 
General procedure for THP deprotection (13, 22). PPTS (25 mg, 0.1 mmol) 
was added to the solution of THP protected alcohol (1 mmol) in EtOH (10 mL). The 
resulted solution was stirred at 55 oC for 1 h. Then solution was cooled down to room 
temperature. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate. 
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General procedure for phthalimide coupling (4, 10). A solution of DIAD (223 
mg, 1.1 mmol) in THF (1 mL) was added dropwise via a syringe to a solution of an 
alcohol (1 mmol), phthalimide (162 mg, 1.1 mmol), and PPh3 (289 mg, 1.1 mmol), in 
THF (4 mL) at the room temperature.  After stirring overnight the solvent was removed at 
reduced pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate. 
Cramer procedure for phosphorylation (18, 23). Phosphorylations were 
performed on 200 µmol scale according to the procedure of Keller and Thompson.29 To 
the alcohol (200 µmol) in CH3CN (2 mL) was added CCl3CN (0.5 mL, 5 mmol), and 
TEAP solution was added in three portions after a 5-min period (3x0.5 mL). The TEAP 
solution was prepared by slowly mixing 9.1 mL of solution A and 1.5 mL of solution B at 
0 oC. Solution A consisted of concentrated phosphoric acid (2.5 mL) in CH3CN (9.4 mL), 
and solution B of triethyl amine (11 mL) in CH3CN (10 mL). The reaction mixture was 
allowed to stir for 0.5 h at room temperature. Solvents were removed at reduced pressure, 
and the residue was chromatographed on silica with elution by iPrOH:H2O:NH4OH 
(6:0.5:2.5 v/v/v). The fractions were analyzed by silica TLC in iPrOH:H2O:NH4OH 
(6:1:3 v/v/v) and visualized by p-anisaldehyde. The fractions containing the product were 
concentrated under reduced pressure, and lyophilized.  
Preparation of NaIO4 on SiO2. NaIO4 (2 g) was dissolved in 10 mL of deionized 
H2O at 70 oC. The solution was then added to a suspension of SiO2 (20 g) in 40 mL of 
deionized H2O. The mixture was stirred at 20 oC for 30 min. H2O was removed using a 
rotary evaporator. Two portions of benzene (50 mL) were added and evaporated 
similarly. The reagent was dried in vacuo using an oil pump with gentle heating for 3 h.  
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(E)-4-Hydroxy-E-3-methyl-but-2-enoic acid ethyl ester (3). To a 250 mL round 
bottom flask was loaded NaIO4 on SiO2 (100.74 g, 47.1 mmol, 10% by weight), L-(+)-
diethyl tartrate (3.24 g, 15.7 mmol) and 2-(triphenylphosphoranylidene) propionaldehyde 
ylid (5 g, 15.7 mmol) in CH2Cl2 (200 mL). After stirring overnight, the solution was 
filtered. The white solid was washed with 200 mL of ether, and the combined organic 
layers were concentrated under reduced pressure. The residue was redissolved in EtOH. 
To the resulting solution was added CeCl3 heptahydrate (17.57 g, 47.1 mmol) and when 
the reagent had dissolved NaBH4 (1.78 g, 47.1 mmol) was added in small portions during 
15 min. The resulted mixture was stirred overnight. The pH of the solution was then 
adjusted to 7 using 1M HCl, and the solvent was removed at reduced pressure. The 
aqueous layer was saturated with NaCl and extracted with ether (3x50 mL). The ether 
layers were combined, washed with saturated Na2CO3 and brine, and dried over Na2SO4. 
The solvent was removed at reduced pressure, and the residue was chromatographed on 
silica with gradient elution by hexanes/ethyl acetate to give 1.92 g (84%) of product 3 as 
colorless oil. Rf 0.39 (hexanes:ethyl acetate  2:3); 1H NMR (CDCl3, 300 MHz) δ 1.28 
(3H, t, J
 
= 8.0 Hz, CH3), 2.09 (3H, t, J = 0.6 Hz, CH3), 2.30 (1H, s, OH), 4.13 (2H, s, 
CH2), 4.17 (2H, q, J = 8.0 Hz, CH2) 5.98 (1H, m, J = 1.7 Hz, CH); 13C NMR (CDCl3, 75 
MHz) δ 13.95, 15.28, 59.58, 66.38, 113.07, 157.73, 167.02; HRMS (EI) calcd. for 
C7H12O3 144.0786, found 144.0789. 
(E)-4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-but-2-enoic acid ethyl 
ester (4). Alcohol 3 (100 mg, 0.7 mmol) was converted into phthalimide 4 using the 
general procedure described above. The residue was chromatographed on silica with 
gradient elution by hexanes/ethyl acetate to give 144 mg (76%) of product 4 as white 
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solid. Rf 0.36 (hexanes:ethyl acetate  3:2); mp=128-129 oC (EtOH); 1H NMR (CDCl3, 
300 MHz) δ 1.24 (3H, s, J = 8.0 Hz, CH3), 2.22 (3H, t, J = 0.7 Hz, CH3), 4.13 (2H, q, J = 
8.0 Hz, CH2), 4.31 (2H, d, J = 0.7 Hz, CH2), 5.64 (1H, m, J = 1.7 Hz, CH), 7.46 (2H, d, J 
= 5.6 Hz, 2CH), 7.81 (2H, d, J
 
= 5.6 Hz, 2CH); 13C NMR (CDCl3, 75 MHz) δ 14.22, 
16.88, 44.45, 59.89, 115.97, 123.59, 131.84, 134.27, 151.67, 166.00, 167.75; HRMS (CI) 
calcd. for C15H16NO4 [M+H+] 274.1079, found 274.1097. 
(E)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methyl-but-2-enoic acid ethyl ester 
(6). Under nitrogen atmosphere, TBDMSCl (2.88 g, 19.10 mmol) in DMF (20 mL) was 
added dropwise into solution of alcohol 3 (2.5 g, 17.36 mmol) and imidazole (1.77 g, 
26.04 mmol) in DMF (20 mL). The resulted mixture was stirred overnight at room 
temperature. The progress of the reaction was followed by TLC. The solution was 
transferred into a separation funnel containing 500 mL of water, extracted with Et2O 
(3x50 mL) and the combined extracts were dried over Na2SO4. The solvent was removed 
at reduced pressure, and the residue was chromatographed on silica with gradient elution 
by hexanes/ethyl acetate to give 4.5 g (86%) of product 6 as colorless oil. Rf 0.67 
(hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 0.07 (6H, s, 2CH3), 0.90 (9H, 
s, 3CH3), 1.17 (3H, s, CH3), 1.30 (3H, t, J1 = 8 Hz, CH3), 4.24 (2H, m, CH2), 3.57 (2H, 
dd, J1 = 47 Hz, J2 = 11 Hz, CH2), 5.32 (1H, t, J = 1.Hz, CH); 13C NMR (CDCl3, 75 MHz) 
δ -5.47, 14.34, 15.42, 18,35, 25.86, 59.57, 67.08, 113.32, 157.16, 167.10;  HRMS 
(FTMS) calcd. for C13H27O3Si [M+H+] 259.1729, found 259.1724. 
(E)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methyl-but-2-en-1-ol (7). Under 
nitrogen atmosphere, a solution of 1M DIBALH in hexanes (62 mL, 62 mmol) was added 
dropwise via a syringe to a solution of ester 6 (4 g, 15.5 mmol) in THF (60 mL) at –78 
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0C. The mixture was stirred for 5 h. The temperature was allowed to rise to –40 0C. After 
the addition of brine (20 mL), the mixture was stirred for 30 min at room temperature. 
The solution was filtered through celite®, and the filter cake was washed with ether (3x20 
mL). NaCl was added until the phases separated. The organic layer was removed, and the 
aqueous layer was extracted with ether (3x30 mL). The organic layers were combined, 
and dried over Na2SO4. The solvent was removed at reduced pressure, and the residue 
was chromatographed on silica with gradient elution by hexanes/ethyl acetate to give 
2.85 g (85%) of product 7 as colorless oil. Rf 0.36 (hexanes:ethyl acetate  3:2); 1H NMR 
(CDCl3, 300 MHz) δ 0.08 (6H, s, 2CH3), 0.92 (9H, s, 3CH3), 1.25 (1H, t, J = 6 Hz, OH), 
1.65 (3H, t, J
 
= 0.6 Hz, CH3), 4.03 (2H, s, CH2), 4.21 (2H, t, J = 6 Hz, CH2), 5.68 (1H, m, 
CH); 13C NMR (CDCl3, 75 MHz) δ -5.37, 13.47, 18.38, 25.90, 59.09, 67.62, 122.51, 
138.25; HRMS (FTMS) calcd. for C11H25O2Si [M+H+]217.1624, found 217.1619. 
(E)-tert-Butyl-dimethyl-[2-methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-
enyloxy]-silane (8). To alcohol 7 (2.5 g, 11.55 mmol) in CH2Cl2 (60 mL) was added 3,4-
dihydro-2H-pyran (1.46 g, 17.33mmol) in CH2Cl2 (10 mL), and PPTS (289 mg, 1.16 
mmol) in CH2Cl2 (1 mL). After stirring overnight, the solution was washed with saturated 
NaHCO3 (10 mL). The layers were separated, and the aqueous layer was extracted with 
CH2Cl2 (3x20 mL). The combined organic extracts were dried over Na2SO4. The solvent 
was removed at reduced pressure, and the residue was chromatographed on silica with 
gradient elution by hexanes/ethyl acetate to give 2.7 g (78%) of product 8 as colorless oil. 
Rf 0.78 (hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 0.07 (6H, s, 2CH3), 
0.91 (9H, s, 3CH3), 1.65 (9H, m, CH3, 3CH2), 3.51 (1H, m, CH), 3.90 (1H, m, CH), 4.04 
(2H, s, CH2), 4.1 (1H, dd, J1 = 12 Hz, J2 = 5 Hz,  CH), 4.27 (1H, dd, J1 = 12 Hz, J2 = 5 Hz, 
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CH), 4.63 (1H, m, CH), 5.63 (1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ -5.34, 13.61, 
18.39, 19.55, 25.49, 25.92, 30.67, 62.26, 63.16, 67.88, 97.76, 120.18, 138.89; HRMS 
(MALDI) calcd. for C16H32O3SiNa [M+Na+] 323.2013, found 323.2005. 
(E)-2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-en-1-ol (9). Under nitrogen 
atmosphere, Et3N-3HF complex (10.8 g, 67 mmol) in THF (20 mL) was added dropwise 
to the solution of corresponding protected alcohol 8 (2 g, 6.7 mmol) in THF (20 mL). 
After stirring overnight, Et3N (10 mL) was added. The solvent was removed at reduced 
pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate to give 1.1 g (87%) of product 9 as colorless oil. Rf 0.36 
(hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.71 (10H, m, CH3, 3CH2, 
OH), 3.53 (1H, m, CH), 3.89 (1H, m, CH), 4.04 (2H, d, J = 0.6 Hz, CH2), 4.07 (1H, dd, J1 
= 12 Hz, J2 = 5 Hz, CH), 4.30 (1H, dd, J1 = 12 Hz, J2 = 5 Hz, CH), 4.65 (1H, m, CH), 5.64 
(1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ 13.77, 19.44, 25.37, 30.57, 62.21, 63.22, 
67.96, 98.01, 121.13, 139.12; HRMS (MALDI) calcd. for C10H18O3Na [M+Na+] 
209.1148, found 209.1150. 
(E)-2-[2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyl]-isoindole-1,3-dione 
(10). Alcohol 9 (850 mg, 4.5 mmol) was converted into phthalimide 10 using the general 
procedure described above. The residue was chromatographed on silica with gradient 
elution by hexanes/ethyl acetate to give 1.1 g (77%) of product 10 as white solid. mp=58-
59 oC; Rf 0.66 (hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.64 (9H, m, 
CH3, 3CH2), 3.48 (1H, m, CH), 3.84 (1H, m, CH), 4.05 (1H, m, CH), 4.23 (3H, m, CH, 
CH2), 4.59 (1H, m, CH), 5.52 (1H, m, CH), 7.74 (2H, m, 2CH), 7.85 (2H, m, 2CH); 13C 
NMR (CDCl3, 75 MHz) δ 14.95, 19.40, 25.40, 30.54, 44.45, 62.12, 63.11, 97.75, 123.32, 
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123.56, 132.01, 133.34, 133.98, 134.28, 168.10; HRMS (MALDI) calcd. for 
C18H21NO4Na [M+Na+] 338.1363, found 338.1368. 
(E)-2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enylamine (11). To a 
solution of phthalimide 10 (445 mg, 1.4 mmol) in EtOH (10 mL) was added hydrazine 
hydrate (210 mg, 4.2 mmol) in EtOH (2 mL). The solution was warmed to 50 0C and 
stirred at that temperature for 30 min, followed by refluxing for 2 h. The solution was 
allowed to cool and filtered. The filter cake was washed with EtOH (3x10 mL). The 
filtrates were combined and solvent was removed at reduced pressure. Ether (20 mL) and  
1M NaOH were added (5 mL) to adjust the pH to 12. The aqueous layer was saturated 
with NaCl and extracted with ether (3x20 mL). The combined organic extracts were dried 
over Na2SO4. The solvent was removed at reduced pressure to give 1.1 g (54%) of 
product 11 as yellow oil, which was used without further purification.  
(E)-[2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyl]-carbamic acid 9H-
fluoren-9-ylmethyl ester (12). To a solution of amino ester 11 (480 mg, 2.6 mmol) in 
THF (10 mL) were added in sequence triethyl amine (290 mg, 2.85 mmol) in THF (6 
mL), and N-(9-fluorenylmethoxycarbonyloxy)succinimide (1.3 g, 3.9 mmol) in THF (10 
mL). After stirring overnight solvent was removed at reduced pressure, and the residue 
was purified by chromatography using a silica column, which was eluted with 
hexanes/ethyl acetate by gradient method to give 850 mg (81%) of product 12 as white 
solid. mp=126-127 oC; Rf 0.36 (hexanes:ethyl acetate 3:2); 1H NMR (CDCl3, 300 MHz) 
δ 1.68 (9H, m, CH3, 3CH2), 3.52 (1H, m, CH), 3.77 (2H, d, J = 6 Hz, CH2), 3.88 (1H, m, 
CH), 4.03 (1H, dd, J1 = 12 Hz, J2 = 5 Hz, CH), 4.25 (2H, m, 2CH), 4.42 (2H, d, J = 3.4 
Hz, CH2), 4.62 (1H, m, CH), 4.86 (1H, s broad, 1NH), 5.52 (1H, m, CH), 7.31 (2H, dt, J1 
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= 7.5 Hz, J2 = 1.2 Hz, 2CH), 7.40 (2H, t, J = 7.5 Hz, 2CH), 7.59 (2H, d, J1 = 7.5 Hz, 
2CH), 7.76 (2H, d, J
 
= 7.5 Hz, 2CH); 13C NMR (CDCl3, 75 MHz) δ 14.65, 19.53, 25.40, 
30.62, 47.25, 47.93, 62.32, 63.34, 66.65, 98.19, 119.95, 121.99, 125.01, 127.01, 127.65, 
136.36, 141.29, 143.91, 156.38; HRMS (MALDI) calcd. for C25H29NO4Na [M+Na+] 
430.1989, found 430.1983. 
(E)-(4-Hydroxy-2-methyl-but-2-enyl)-carbamic acid 9H-fluoren-9-ylmethyl 
ester (13). An acetal 12 (850 mg, 2.08 mmol) was deprotected following the general 
procedure for THP deprotection described above. The residue was chromatographed on 
silica with gradient elution by hexanes/ethyl acetate to give 532 mg (79%) of product 13 
as white solid. mp=131-133 oC; Rf 0.21 (hexanes:ethyl acetate  2:3); 1H NMR (CDCl3, 
300 MHz) δ 1.4 (1H, s broad, OH), 1.67 (3H, s, CH3), 3.74 (2H, d, J = 7 Hz, CH2), 4.21 
(3H, m, CH2, CH), 4.44 (2H, d, J = 7 Hz, CH2), 4.91 (1H, s broad, 1NH), 5.52 (1H, m, 
CH), 7.32 (2H, dt, J1 = 7.5 Hz, J2 = 1.2 Hz, 2CH), 7.40 (2H, m, 2CH), 7.59 (2H, d, J1 = 
7.5 Hz, 2CH), 7.77 (2H, d, J
 
= 7.5 Hz, 2CH); 13C NMR (CDCl3, 75 MHz) δ 14.51, 47.24, 
47.77, 58.95, 66.57, 119.96, 124.33, 124.96, 127.01, 127.65, 135.59, 141.29, 143.86, 
156.43; HRMS (MALDI) calcd. for C20H21NO3Na [M+Na+] 346.1414, found 346.1427. 
(E)-(2-Methyl-but-2-enyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 4-
diphosphate bis ammonium salt (18). An alcohol 13 (65 mg, 20 µmol) was 
phosphorylated according to the Cramer procedure described earlier. The residue was 
chromatographed on silica with elution by iPrOH:H2O:NH4OH (6:0.5:2.5 v/v/v). The 
fractions were analyzed by silica TLC (iPrOH:H2O:NH4OH (6:1:3 v/v/v)) and visualized 
by p-anisaldehyde. The fractions containing the product were concentrated under reduced 
pressure, and then lyophilized to give 46 mg (44%) of product 18 as white solid. Rf 0.30 
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(iPrOH:H2O:NH4OH (6:1:3 v/v/v)); 1H NMR (D2O, 300 MHz) δ 1.53 (3H, s, CH3), 3.52 
(2H, s, CH2), 4.25 (1H, m, CH), 4.43 (2H, t, J = 6.3 Hz, CH2), 4.55 (2H, d, J = 4.8 Hz, 
CH2), 5.34 (1H, m, CH), 7.36 - 7.49 (4H, m, 4CH), 7.65 (2H, d, J1 = 7.5 Hz, 2CH), 7.87 
(2H, d, J
 
= 7.5 Hz, 2CH); 13C NMR (D2O, 75 MHz) δ 13.77, 23.76, 47.30, 62.08, 66.03, 
81.71, 120.24, 125.07, 127.58, 128.14, 137.61, 141.10, 143.93, 158.45; 31P NMR (D2O, 
125 MHz) δ -9.73 (d, J = 22 Hz), -6.92 (d, J = 22 Hz); HRMS (MALDI) calcd. for 
C20H22NO9P2 [M-H] 482.0775, found 482.0759. 
(E)-4-Amino-3-methylbut-2-enyl diphosphate bis ammonium salt (15). A 
diphosphate 18 (120 mg, 0.23 µmol) was added to piperidine (5 mL) and stirred for 1 h at 
room temperature. The piperidine was removed, and the residue was purified on silica 
with elution by iPrOH:H2O:NH4OH (6:0.5:2.5 v/v/v). The fractions were analyzed by 
silica TLC (iPrOH:H2O:NH4OH (6:1:3 v/v/v)) and visualized by p-anisaldehyde. The 
fractions containing the product were concentrated under reduced pressure, and then 
lyophilized to give 58 mg (85%) of product 15 as white solid. Rf 0.1 
(iPrOH:H2O:NH4OH (6:1:3 v/v/v)); 1H NMR (D2O, 300 MHz) δ 1.53 (3H, s, CH3), 3.07 
(2H, s, CH2), 4.32 (2H, t, J = 8 Hz, CH2), 5.41 (1H, m, CH); 13C NMR (D2O, 75 MHz) δ 
14.36, 45.51, 62.14, 62.20, 125.58, 131.94; 31P NMR (D2O, 125 MHz) δ -9.73 (d, J = 22 
Hz), -6.92 (d, J = 22 Hz); HRMS (MALDI) calcd. for C5H12NO7P2 [M-H] 260.0095, 
found 260.0092. 
(E)-Thioacetic acid S-[2-methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyl] 
ester (19). To NCS (176 mg, 1.29 mmol) in CH2CL2 (4 mL) at -40 oC was added DMS 
(103 µL, 1.39 mmol) in CH2CL2 (3 mL). The mixture was stirred for 10 min at 0 oC, 
cooled down to -40 oC, and alcohol 9 (200 mg, 1.07 mmol) in CH2CL2 (3 mL) was added 
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dropwise. The mixture was stirred for 2 h at 0 oC and periodically monitored by silica 
TLC. When the starting material had disappeared, the reaction was quenched with brine 
(10 mL). The layers were separated, and the aqueous layer was extracted with CH2CL2 
(3x10 mL). Organic layers were combined and dried over Na2SO4. The residue was 
concentrated under reduced pressure and redissolved in DMF (2 mL). KSAc (499 mg, 
4.28 mmol) in DMF (8 mL) was added at room temperature, and the solution was stirred 
overnight. H2O (100 mL) was added and the product was extracted with ether (3x20 mL). 
The organic layer was washed with saturated NaHCO3 (4x30 mL) and brine (30 mL). 
Organic layers were combined and dried over Na2SO4. The solvent was removed at 
reduced pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate to give 228 mg (87%) of product 19 as colorless oil. Rf 0.51 
(hexanes:ethyl acetate 1:1); 1H NMR (CDCl3, 300 MHz) δ 1.67 (9H, m, CH3, 3CH2), 
2.35 (3H, s, CH3), 3.51 (1H, m, CH), 3.58 (1H, m, CH), 3.87 (2H, s, CH2), 4.02 (1H, dd, 
J1 = 12 Hz, J2 = 5 Hz,  CH), 4.23 (1H, dd, J1 = 12 Hz, J2 = 5 Hz,  CH),  4.61 (1H, m, CH), 
5.62 (1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ 15.51, 19.48, 25.43, 30.47, 30.60, 
37.68, 62.24, 63.44, 97.96, 124.98, 134.81; HRMS (MALDI) calcd. for C12H20O3SNa 
[M+Na+] 267.1025, found 267.1026. 
(E)-2-[2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyldisulfanyl]-pyridine 
(21). To a solution of thioacetate 19 (245 mg, 1 mmol) and 2,2’-pyridine disulfide (661 
mg, 3 mmol) in CH3OH (10 mL) was added 30% wt solution of CH3ONa in CH3OH (180 
mg, 1 mmol) at -40 oC. The mixture was left in a freezer at -20 oC overnight without 
stirring. The solution was concentrated under reduced pressure, and the residue was 
purified by chromatographed on silica with gradient elution by hexanes/ethyl acetate to 
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give 256 mg (82%) of product 21 as colorless oil. Rf 0.38 (hexanes:ethyl acetate  3:2); 1H 
NMR (CDCl3, 300 MHz) δ 1.68 (9H, m, CH3, 3CH2), 3.41 (2H, s, CH2), 3.49 (1H, m, 
CH), 3.84 (1H, m, CH), 3.94 (1H, dd, J1 = 12 Hz, J2 = 5 Hz,  CH), 4.13 (1H, dd, J1 = 12 
Hz, J2 = 5 Hz,  CH), 4.57 (1H, m, CH), 5.50 (1H, m, CH), 7.07 (1H, m, CH), 7.63 (2H, 
m, 2CH), 8.45 (1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ 15.55, 19.45, 25.41, 30.59, 
48.23, 62.21, 63.32, 97.80, 119.68, 120.50, 127.00, 133.41, 136.76, 149.56, 160.24; 
HRMS (MALDI) calcd. for C15H22NO2S2 [M+H+] 312.1086, found 312.1097. 
(E)-3-Methyl-4-(pyridin-2-yldisulfanyl)-but-2-en-1-ol (22). Acetal 21 (830 mg, 
2.6 mmol) was deprotected following the general procedure for THP deprotection 
described above. The residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate to give 540 mg (89%) of product 22 as colorless oil. Rf 0.43 
(hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.56 (1H, t, J = 6 Hz, OH), 
1.69 (3H, s, CH3), 3.37 (2H, d, J = 1 Hz, CH2), 4.03 (2H, d, J = 6 Hz, CH2), 5.53 (1H, m, 
CH), 7.09 (1H, m, CH), 7.65 (2H, m, 2CH), 8.45 (1H, m, CH); 13C NMR (CDCl3, 75 
MHz) δ 15.21, 47.97, 59.11, 120.80, 120.86, 129.98, 132.58, 136.92, 149.36, 160.53; 
HRMS (MALDI) calcd. for C10H14NOS2 [M+H+] 228.0511, found 228.0521. 
(E)-[3-Methyl-4-(pyridin-2-yldisulfanyl)-but-2-enyl] diphosphate ammonium 
salt (23). An alcohol 22 (46 mg, 20 µmol) was phosphorylated according to the Cramer 
procedure described earlier. The residue was chromatographed on silica eluted by 
iPrOH:H2O:NH4OH (6:0.5:2.5 v/v/v). The fractions were analyzed by silica TLC 
(iPrOH:H2O:NH4OH (6:1:3 v/v/v)) and visualized by p-anisaldehyde. The fractions 
containing the product were concentrated under reduced pressure, and then lyophilized to 
give 17 mg (20 %) of product 23 as white solid. Rf 0.32 (iPrOH:H2O:NH4OH (6:1:3 
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v/v/v)); 1H NMR (D2O, 300 MHz) δ 1.63 (3H, s, CH3), 3.40 (2H, s, CH2), 4.17 (2H, d, J 
= 7 Hz, CH2), 5.53 (1H, m, CH), 7.22 (1H, m, CH), 7.75 (2H, m, 2CH), 8.32 (1H, d, J = 
5Hz, CH); 13C NMR (D2O, 75 MHz) δ 14.73, 47.75, 62.32, 62.39, 122.03, 122.15, 
126.26, 126.37, 134.91, 138.55, 149.02, 158.91; 31P NMR (D2O, 125 MHz) δ -9.73 (d, J 
= 22 Hz), -6.92 (d, J = 22 Hz); HRMS (MALDI) calcd. for C10H14NO7S2P2 [M-H] 
385.9692, found 385.9702. 
(E)-(4-Mercapto-3-methyl-but-2-enyl) diphosphate ammonium salt (24). To 
diphosphate 23 (50 mg, 0.12 mmol) in 100 mM NH4HCO3 (1 mL) was added DTT (55 
mg, 0.36 mmol) in 100 mM NH4HCO3 (1 mL). The mixture was allowed to stir for 1 h at 
room temperature. The mixture was lyophilized, and the residue was chromatographed on 
cellulose with elution by 100 mM NH4HCO3:iPrOH (2:8 v/v). The fractions were 
analyzed by silica TLC (iPrOH:H2O:NH4OH (6:1:3 v/v/v)) and visualized by p-
anisaldehyde. The fractions containing the product were concentrated under reduced 
pressure, and then lyophilized to give 17 mg (90%) of product 24 as white solid. Rf 0.32 
(iPrOH:H2O:NH4OH (6:1:3 v/v/v)); 1H NMR (D2O, 300 MHz) δ 179 (3H, s, CH3), 3.18 
(2H, s, CH2), 4.47 (2H, t, J = 8 Hz, CH2), 5.62 (1H, m, CH);  13C NMR (D2O, 75 MHz) δ  
14.45, 32.37, 62.61, 62.68, 121.89, 122.00, 125.12; 31P NMR (D2O, 125 MHz) δ -9.73 
(d, J = 22 Hz), -6.92 (d, J = 22 Hz); HRMS (MALDI) calcd. for C5H11O7SP2 [M-H] 
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SYNTHESIS  AND  EVALUATION  OF  





The MEP pathway begins with the condensation of glyceraldehyde phosphate and 
pyruvate to form 1-deoxy-D-xylulose-5-phosphate (DXP) catalyzed by DXP synthase.  
DXP is then rearranged and reduced by MEP synthase to produce methylerythritol 
phosphate (MEP).  MEP is converted into methylerythritol cyclodiphosphate (cMEPP) by 
the consecutive actions of three enzymes: CDP-ME synthase, CDP-ME kinase, cMEPP 
synthase. A reductive ring opening of cMEPP provides hydroxydimethylallyl 
diphosphate (HDMAPP). The IspH catalyzes the final step of the MEP pathway – 
formation of IPP and DMAPP. It is interesting to note that in contrast to the mevalonate 
(MVA) pathway, organisms utilizing the MEP pathway do not require IPP isomerase 
activity. However, the IPP isomerase is found in most organisms (Scheme 3.1).1  
This chapter describes the synthesis and evaluation of analogues as alternative 
substrates for methylerythritol phosphate (MEP): aminomethylerythritol phosphate 
(NMEP), methylerythritol thiophosphate (MESP), and thiomethylerythritol phosphate 




























































































Scheme 3.1. Methylerythritol Phosphate (MEP) Pathway. 
 
Several inhibitors, which are diphosphate analogues, have been synthesized by 
replacing the diphosphate group with less reactive or unreactive moieties, such as 
phosphonophosphates,2 phosphonophosphinates,3 and bisphosphonates.4 Typically, these 
compounds are not especially potent prenyltransferase inhibitors, since the pKa of these 
groups are different from the normal diphosphates. In contrast, thiophosphate analogues 
of isopentenyl diphosphate (IPP), dimethylallyl diphosphate (DMAPP), geranyl 
diphosphate (GPP), farnesyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP) 






Figure 3.1. Proposed analogues for MEP. 
 
leaving group.  Kinetic studies revealed that geranyl thiodiphosphate (GSPP) binds to the 
allylic site in FPPase with excellent selectivity and affinity, and is an efficient 
competitive inhibitor of FPPase (the reaction of IPP with GSPP is estimated to be 105 
times slower than for GPP).  
In this chapter, the question of how changes in MEP affect the enzymatic 
conversion of the alternative substrates to cMEPP analogues by the consecutive action of 
three proteins in the MEP pathway, IspD, IspE, and IspF is addressed. The analogues 
were evaluated as alternative substrates or inhibitors of IspDF (bifunctional protein, with 








Rationale for Aminomethylerythritol  
Phosphate 
The primary hydroxy group of MEP is not directly involved in the enzymatic 
conversion of MEP to HDMAPP except perhaps through binding. Aminomethylerythritol 
phosphate analogue (NMEP) could potentially be recognized by the respective enzymes 
and converted into cNMEPP (Scheme 3.2). The mechanism for the conversion of cMEPP 
to HDMAPP (Scheme 3.1) catalyzed by IspG is not known. Two suggestions for this step 
were discussed in the previous chapter (Chapter 2, Schemes 2.2 and 2.3).6 Accordingly, 
the reaction may proceeds by either a cationic or a radical mechanism. In both cases, the 
primary hydroxyl group of MEP is oxidized to an aldehyde.  
 
 





 In a similar manner, the amino group in NMEP could be oxidized to an imine. 
However, the amine should be protonated at physiological pH and the ammonium species 
should resist oxidation. Therefore, NMEP might be converted to intermediates that 
inhibit the enzymes starting from IspG in the pathway. Additionally, this analogue will 
ultimately inhibit the IspH when it is converted to NDMAPP. The synthesis and activity 
of the aminodimethylallyl diphosphate (NDMAPP) with IspH is discussed separately in 
Chapter 2. It was previously shown by our collaborators in France that NDMAPP is a 
potent nanomolar inhibitor of IspH. 
 
Synthesis of Aminomethylerythritol  
Phosphate 
The synthesis of NMEP begins with the synthesis of Z α,β-unsaturated ester 27 
from propargyl alcohol, as described in the literature (Scheme 3.3).7 Propargyl alcohol 
was protected as a TBDMS ether. The acetylenic proton of 25 was removed with nBuLi 
and the resulting anion was treated with chloroformate to provide ester 26. The ester 27 
was prepared from 26 by the method of Corey and Katzenellenbogen,8 to give the Z 
isomer exclusively. It should be noted that exclusive formation of the Z isomer requires 
slow addition of a 1M solution of ester 26 in THF to the methyl cuprate at -78 oC. The 
yield of the reaction is increased when the reaction is quenched with MeOH that has been 






Scheme 3.3. Synthesis of Z α,β-unsaturated ester 27. 
 
Reduction of 27 ester with DIBALH at -40 oC gave alcohol 28, which was then 
protected with the THP protecting group (Scheme 3.4). Alcohol 29 was phosphorylated 
using benzyl phosphite-iodine procedure,9 and the TBDMS group was removed with the 
triethylamine hydrofluoride complex10 to give 30. The amino group was introduced by 
treating alcohol 30 with phthalimide under Mitsunobu conditions.11 However, all 



































































Alcohol 28 was then protected with THP, and the TBDMS group of 33 was 
removed with the triethylamine hydrofluoride complex (Scheme 3.5). The amino group 
was then introduced by treating the alcohol 34 with phthalimide under Mitsunobu 
conditions.11 The phthalimide moiety was removed with hydrazine and the resulting 
amine was protected with di-tert-butyl dicarbonate to give 37.  
After removal of the THP group, alcohol 38 was phosphorylated using benzyl 
phosphite-iodine (Scheme 3.6).9 The Sharpless asymmetric dihydroxylation12 established 
two chiral centers of 40, according to the Sharpless mnemonic device.13 The er ratio was 
found to be 12/1 using chiral HPLC. NMEP was obtained after deprotection of 40 by 
treatment with H2 and Pd/C to remove the benzyl groups, followed by HCl to remove the 
Boc group (Scheme 3.6). 
 
 






Scheme 3.6. Synthesis of NMEP. 
 
Enzymatic Evaluation of Aminomethylerythritol  
Phosphate 
NMEP was tested as an alternative substrate and as an inhibitor of IspDF and IspE 
for the sequence of reactions NMEP → CDP-NME → CDP-NMEP → cNMEPP. These 
transformations were detected by the 32P assay in presence of radiolabelled and cold CTP 
and ATP and by LCMS. The experiments with 32P were analyzed by TLC as described in 
the literature.14,15 A typical TLC analysis is shown in Figure 3.2. Samples were 
preincubated for 5 min in the presence of all substrates, except for radiolabeled ATP and 
CTP. Reactions were initiated by addition of CTP. After 15 min, the reactions were 
quenched with 50 µL of methanol and were put on ice. TLC (Polygram Sil N-HR; 
Macherey & Nagel) was performed by spotting 3.5 µL of the reaction mixture and 






Reaction conditions: lane 1: MEP + CTP, 
ATP, IspDF, IspE; lane 2: MEP + CTP, 
ATP, IspDF, IspE; lane 3: MEP + CTP, 
ATP, mutant IspD, IspE; lane 4: NMEP + 
CTP, ATP, IspDF, IspE; lane 5: NMEP + 
CTP, ATP, mutant IspD; lane 6: NMEP + 
CTP, ATP, mutant IspD, IspE; lane 7: 
NMEP + CTP cold, ATP, IspDF, IspE; 
lane 8: NMEP + CTP, ATP cold, IspDF, 












Figure 3.2. TLC plate showing the different products following incubation of MEP and 
NMEP (500 µM), IspDF (4.8 µM), IspE (6.2 µM), γ-[32P]ATP (150 µM, 320 µCi/µmol), 
α-[32P]CTP (150 µM, 40 µCi/µmol) after 1 h reaction. 
 
As seen from Figure 3.2, the TLC data indicate that NMEP is a substrate for the 
IspDF and IspE. Potential intermediates are listed in Figure 3.3. To establish the identity 
of the products, a set of LCMS experiments were performed as shown in Figures 3.4 and 
3.5 following procedures described in the literature.16 After 30 min, reaction was 
quenched with MeOH and the proteins were removed by filtration. A 15 µL sample was 
injected into the HPLC column and the eluents were analyzed by mass spray analysis. 
CDP-NME, CDP-NMEP, cNMEPP were selected by extracting corresponding masses 
from the spectrum. The comparison of isotope distribution of the extracted compounds 






















































m/z: 519.09 (100.0%), 520.09 (17.1%), 
521.09 (2.9%), 521.10 (1.2%)




m/z: 599.06 (100.0%), 600.06 (16.1%), 
601.06 (4.7%), 600.05 (1.5%)










Figure 3.3. Potential intermediates for enzymatic conversion of NMEP to cNMEPP. 
 
substrate for both reactions catalyzed by IspDF, and for IspE to give cNMEPP using 
selective ion-monitoring. 
 
Rationale for Methylerythritol  
Thiophosphate 
The considerations outlined in the rationale section for NMEP analogue led us to 
consider a methylerythritol thiophosphate analogue, where the phosphate oxygen atom 
attached to the alkyl group is replaced with sulfur. Since it is known that thiophosphate 
analogues of isopentenyl diphosphate (ISPP) inhibit prenyl transfer,5 MESP might serve 
as a surrogate for DMASPP by functioning as an alternative substrate for the MEP 
pathway enzymes (Scheme 3.7). Isoprenoid biosynthesis would then be blocked during 
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Figure 3.4. LC-MS chromatograms ofthe different products formed after incubation ofNMEP with IspDF, mutant IspD, IspE: 
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Scheme 3.7. Proposed metabolism for MESP. 
 
Synthesis of Methylerythritol  
Thiophosphate 
The synthesis of MESP is shown in Schemes 3.8 and 3.9. Ester 27 from Scheme 
4 was asymmetrically dihydroxylated using Sharpless reaction (Scheme 3.8).12 The 
Mosher ester analysis of 43 showed 18/1 ratio between enantiomers.17 Diol 43 was first 
protected as an acetonide. However, the protecting group would not be removed without 
decomposition of the molecule. Therefore, the diol 43 was protected as an orthoester 44. 
Although the reaction proceeded in quantative yield, 44 was unstable on a silica column. 
After the purification, the product was obtained in 51% yield. In order to improve yield, 







Scheme 3.8. Synthesis of orthoester 46.  
 
a quantitative yield. Again, the alcohol was unstable on silica, and 45 was obtained in 
61% yield after purification. Again, in order to improve yield, we omitted the purification 
step; only aqueous workup was performed for alcohol 45. Alcohol 45 was converted into 
tosylate 46 with isolated yield of 89% yield for the three steps. Tosylate 46 was 
sufficiently stable to be chromatographed on silica.  
The orthoester was cleaved first by mild treatment with HCl to give a formate 
ester, followed by hydrolysis with ammonia in CH3OH to give 48. It is interesting to note 
that the TBDMS protecting group was cleaved by triethyl amine hydrofluoride complex 
in the presence of the orthoester and tosylate group to produce 47. Using tBuOK as a 
bulky base, diol 48 was converted to epoxide 49. The TBDMS group was removed to 
give epoxide 50, and 50 was opened with trisodium thiophosphate salt to give MESP (51) 






Scheme 3.9. Synthesis of MESP. 
 
Enzymatic Evaluation of Methylerythritol  
Thiophosphate 
MESP was evaluated as an alternative substrate for IspDF, and IspE using the 
procedure described for NMEP in transformation: MESP → CDP-MESP → CDP-MESP 
→ cMESPP. The transformation was followed by the 32P TLC in presence of 
radiolabelled and cold CTP and ATP14,15 and by LCMS. Samples were preincubated for 5 
min in the presence of all substrates, except for radiolabeled ATP and CTP. Reactions 
were initiated by addition of CTP. After 15 min, the reactions were quenched with 50 µL 
of methanol and were put on ice. TLC analysis was performed by spotting 3.5 µL of the 
reaction mixture and developing the plates with 1-propanol/ethyl acetate/H2O (6:1:3 
v/v/v). As it can be seen from Figure 3.6, MESP is a better alternative substrate for the 
IspDF and IspE than NMEP. Possible intermediates are listed in Figure 3.7. The 








 Reaction conditions: lane 1: MEP + CTP, 
ATP, IspDF, IspE; lane 2: MESP + CTP, 
ATP, IspDF, IspE; lane 3: MESP + CTP, 
ATP, mutant IspD; lane 4: MESP + CTP, 
ATP,  mutant IspD, IspE; lane 5: MESP + 












Figure 3.6. TLC plate showing the different products following incubation of MEP and 
MESP (500 µM), IspDF (4.8 µM), IspE (6.2 µM), γ-[32P]ATP (150 µM, 320 µCi/µmol), 
α-[32P]CTP (150 µM, 40 µCi/µmol) after 1 h reaction. 
 
 
After 30 min incubation, the reaction was quenched with MeOH and the proteins 
were removed by filtration. A 15 µL sample was injected into HPLC and was analyzed 
by electron mass spray analysis. CDP-MES, CDP-MESP, cMESPP were selected by 
extracting corresponding masses from the spectrum. The comparison of isotope 
distribution of the extracted compounds allowed us to assign each metabolite. These 
LCMS experiments establish that MESP is a substrate for IspDF, IspE and is converted to 












Figure 3.7. Possible intermediates for enzymatic conversion of MESP to cMESDP. 
 
Rationale for Thiomethylerythritol  
Phosphate 
 The tertiary hydroxyl group in CDP-ME is phosphorylated by CDP-ME kinase, 
and is later reductively eliminated when cMEPP is converted to HDMAPP. The 
substitution of the tertiary hydroxyl group by a thiol moiety should not appreciably affect 
the kinase activity; however, it may substantially retard elimination step. We were 
interested in investigating the activity of enzymes in the pathway with the 
thiomethylerythritol phosphate as the initial substrate. We speculate that our analogue 





















































































































Scheme 3.10. Proposed metabolism for SMEP. 
 
Synthesis of Thiomethylerythritol  
Phosphate  
The synthesis of SMEP is shown in Schemes 3.11 and 3.12. 3-Methylbut-2-en-1-
ol was treated with TBDPSCl to give 52, followed by selenious acid oxidation to produce 
a 1:2 mixture of E allylic alcohol 54 and aldehyde 53. Aldehyde 53 was reduced with 
NaBH4 to give 54. Alcohol 54 was epoxidized under Sharpless conditions in 12/1 
enantiomeric ratio and resulting epoxy alcohol 55 was converted into bromide 56 using 
the procedure described by Appel.18 Bromide 56 was treated with KSAc to produce 
thioacetate 57. The acetate moiety was removed with MeONa at -40 oC, and the resulting 
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Scheme 3.11. Synthesis of thiirane 58. 
 
The Mosher ester analysis of 58 showed 10/1 enatiomeric ratio (Scheme 3.11). The free 
hydroxyl group of 58 was protected as an acetate to prevent rearrangement during the 
next step, which involves reflux at high temperature (Scheme 3.12). The thiirane ring 
was opened by refluxing 59 in AcOH/Ac2O/AcOK to give triacetate 60.20 A maximal 
yield of 30% was obtained after 12 h. Longer times at reflux resulted in accumulation of 
side products. Consequently, 60 was treated with MeONa at -40 oC in the presence of 
three equivalents of 2,2’-pyridyl disulfide to trap liberated thiol as a mixed disulfide 61. 





Scheme 3.12. Synthesis of SMEP. 
 
deprotected with TBAF to produce alcohol 63. The future steps include phosphorylation 
of 63 and disulfide deprotection to achieve 65. In summary, the synthesis of NMEP and 
MESP analogues of MEP was achieved. These analogues were tested as substrates in the 
MEP pathway and were found to be substrates for CDPME Synthase, CDPME Kinase, 
and cMEPP Synthase. The synthesis of SMEP was initiated and alcohol 63 was prepared. 
The future steps include phosphorylation of 63 and disulfide deprotection as 








NMR spectra were recorded on a Varian Unity Inova NMR 300 MHz FTNMR 
interfaced to a Sun Sparcstation 5 computer at 300 MHz (1H NMR) and 75 MHz (13C 
NMR).  All chemical shifts are reported in parts per million (ppm) and coupling constants 
(J) in hertz (Hz).  1H chemical shifts are referenced relative to the TMS peak at δ 0.0 ppm 
or to the peak of CD2Cl2 at 5.32 ppm.  The 13C chemical shifts are referenced relative to 
CDCl3 at δ 77.0 ppm (center peak), the peak of CD2Cl2 at 54 ppm (center peak), and for 
D2O to MeOH at 49 ppm . 31P chemical shifts are referenced relative to the peak of 
H3PO4 in D2O at δ 0 ppm. 
All commercial reagents were ACS reagent grade and were used without further 
purification. In general all solvents, reagents, and deuterated solvents were purchased 
from Fisher Chemicals, Acros, and Aldrich. Methylene chloride and ethanol were 
distilled from CaH2 prior to use. All other reagents were of commercial quality from 
freshly opened containers. 
Sharpless asymmetric dihydroxylation (40, 43). In a 25 mL flask was dissolved 
AD mix β (3.14 g), NaHCO3 (565 mg, 6.73 mmol), and CH3SO2NH2 (160 mg, 1.68 
mmol) in tBuOH:H2O (1:1 v/v, 12 mL). The solution was cooled to 0 oC, and an alkene 
(0.56 mmol) was added. The mixture was stirred overnight at 0 oC. The reaction was 
quenched with Na2SO3 (3.36 g) at 0 oC. The temperature was allowed to rise to room 
temperature, while the solution was stirred for 1 h. The layers were separated, and the 





were dried over Na2SO4. The solvent was removed at reduced pressure, and the residue 
was chromatographed on silica with gradient elution by hexanes/ethyl acetate. 
General preparation and analysis of Mosher esters.21 The reactions were 
generally run on a 0.15-mmol scale. A mixture 4-(dimethy1amino)pyridine (18 mg, 0.15 
mmol) and triethylamine  (100 µL) in CH2Cl2 (0.5 mL), was treated with the substrate. 
Immediately, 30 µL of neat R-(-)-α-methoxy-(trifluoromethy1)phenylacetyl chloride 
(MTPA chloride) was added. The solution became warm and turned orange. Reactions 
were concentrated under reduced pressure, and the residue was chromatographed on 
silica with gradient elution by hexane/ethyl acetate (0% to 20% ethyl acetate). 19F NMR 
analysis focused on the ratio between fluorine signals. 
tert-Butyl-dimethyl-prop-2-ynyloxy-silane (25). TBDMSCl (16.6 g, 0.11 mol) 
was added slowly to a solution of propargyl alcohol (5.6 g, 0.1 mol) and imidazole (10.2 
g, 0.15 mol) in DMF (200 mL) at room temperature. The resulted mixture was stirred 
overnight at room temperature. The solution was transferred into a separation funnel 
containing water (1 L) and was extracted with Et2O (3x200 mL). The combined extracts 
were dried over Na2SO4. The solvent was removed at reduced pressure, and the residue 
was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 2% 
ethyl acetate) to give 14.6 g (86%) of 25 as colorless oil. Rf 0.64 (hexanes:ethyl acetate  
1:1). 1H NMR (CDCl3, 300 MHz) δ 0.13 (6H, s, 2CH3), 0.91 (9H, s, 3CH3), 2.39 (1H, t, J 
= 2.3 Hz, CH), 4.31 (2H, d, J = 2.5 Hz, CH2); 13C NMR (CDCl3, 75 MHz) δ -5.22, 18.27, 
25.77, 51.49, 72.82, 82.39; HRMS (FTMS) calcd. for C9H19OSi [M+H+] 171.12000, 





4-(tert-Butyl-dimethyl-silanyloxy)-but-2-ynoic acid methyl ester (26). To a 
solution of 25 (15 g, 88 mmol) in THF (150 mL) was added 2.5 M solution of nBuLi in 
hexanes (38 mL, 96 mmol) at -78 oC dropwise via an addition funnel. After the addition 
was complete, a solution of methyl chloroformate (12.5 g, 132 mmol) in THF (50 mL) 
was added dropwise over a period of 1 h. The reaction was stirred for 1 h at -78 oC and 
then the mixture was warmed to room temperature over 1 h. The mixture was cooled to -
20 oC and quenched with saturated solution of NH4Cl (200 mL). The layers were 
separated, and the aqueous layer was extracted with ether (3x50 mL). The combined 
organic extracts were  dried over Na2SO4. The solvent was removed at reduced pressure, 
the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate 
(0% to 4% ethyl acetate) to give 18.5 g (92%) of 26 as colorless oil. 1H NMR (CDCl3, 
300 MHz) δ 0.14 (6H, s, 2CH3), 0.91 (9H, s, 3CH3), 3.78 (3H, s, CH3), 4.34 (2H, s, CH2); 
13C NMR (CDCl3, 75 MHz) δ -5.28, 18.20, 25.68, 51.34, 52.72, 76.31, 86.14, 153.75; 
HRMS (FTMS) calcd. for C11H21O3Si [M+H+] 229.12545, found 229.12517. The NMR 
data was identical to the data published before.7 
(Z)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methyl-but-2-enoic acid methyl ester 
(27). To a suspension of CuI (8.34 g, 43.8 mmol) in THF (160 mL) at -78 oC was added 
1.5 M solution of MeLi in THF (58.4 mL, 87.58 mmol). The solution became clear and 
was left to stir for 30 min. A solution of 26 (10 g, 43.8 mmol) in THF (45 mL) was added 
dropwise to the mixture at -78 oC. Precise control of temperature was important in order 
to obtain only Z isomer. After the addition was complete, the mixture was stirred for 2 h 
at the same temperature. The mixture was quenched with MeOH (60 mL) cooled to -78 





extracted with ether (3x50 mL). The combined organic extracts were  dried over Na2SO4. 
The solvent was removed at reduced pressure, the residue was chromatographed on silica 
with gradient elution by hexanes/ethyl acetate (0% to 5% ethyl acetate) to give 8.8 g 
(82%) of 27 as colorless oil. 1H NMR (CDCl3, 300 MHz) δ 0.08 (6H, s, 2CH3), 0.91 (9H, 
s, 3CH3), 1.97-1.98 (3H, m, CH3), 3.67 (3H, s, CH3), 4.79-4.8 (2H, m, CH2), 5.67-5.69 
(1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ -5.49, 18.24, 21.42, 25.84, 50.92, 62.70, 
114.39, 161.35, 166.42; HRMS (FTMS) calcd. for C12H25O3Si [M+H+] 245.15675, found 
245.15722. The NMR data was identical to the data published before.7 
(Z)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methyl-but-2-en-1-ol (28). A solution 
of DIBALH (1M in hexanes, 4 mL, 4 mmol) in THF (10 mL) was added dropwise via a 
syringe to a solution of ester 27 (244 mg, 1 mmol) in THF (6 mL) at –78 0C. The mixture 
was stirred for 3 h while the temperature was allowed to rise to –40 0C. After the addition 
of 0.2 M Na2CO3 (20 mL), the mixture was stirred for 30 min at room temperature. The 
solution was filtrated through celite®, and the filter cake was washed with two 20 mL 
portions of ether. NaCl was added until separation of phases occurred. The aqueous layer 
was extracted with ether (3x20 mL). The combined organic extracts were, and dried over 
Na2SO4. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% 
ethyl acetate) to give 181 mg (84%) of 28 as colorless oil. Rf 0.23 (hexanes:ethyl acetate  
4:1); 1H NMR (CDCl3, 300 MHz) δ 0.09 (6H, s, 2CH3), 0.91 (9H, s, 3CH3), 1.77 (2H, d, 
J = 1 Hz, CH2), 1.81 (1H, s broad, OH), 4.14 (2H, t, J = 5.9 Hz, CH2), 4.17 (2H, s, CH2), 





62.36, 125.70, 139.04; HRMS (FTMS) calcd. for C11H25O2Si [M+H+] 217.16183, found 
217.16161. 
(Z)-tert-Butyl-dimethyl-[2-methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-
enyloxy]-silane (33). Under nitrogen atmosphere to a solution of alcohol 28 (217 mg, 1 
mmol) in CH2Cl2 (6 mL) at room temperature was added 3,4-dihydro-2H-pyran (126 mg, 
1.5 mmol) in of CH2Cl2 (1 mL), and PPTS (25 mg, 0.1 mmol) in CH2Cl2 (1 mL). After 
stirring overnight, the solution was washed with saturated NaHCO3 (10 mL) and 
extracted with CH2Cl2 (3x10 mL). The combined organic extracts were dried over 
Na2SO4. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 10% 
ethyl acetate) to give 295 mg (98%) of 33 as colorless oil. Rf 0.87 (hexanes:ethyl acetate  
1:1); 1H NMR (CDCl3, 300 MHz) δ 0.07 (6H, s, 2CH3), 0.90 (9H, s, 3CH3), 1.49-1.85 
(9H, m, CH3, 3CH2), 3.47-3.54 (1H, m, CH), 3.83-3.91 (1H, m, CH), 3.99-4.06 (1H, s, 
CH), 4.18 (2H, s, CH2), 4.21-4.28 (1H, m, CH), 4.61 (1H, t, J = 2.9 Hz, CH), 5.42 (1H, 
m, CH); 13C NMR (CDCl3, 75 MHz) δ -5.33, 18.33, 19.52, 21.04, 25.45, 25.88, 30.64, 
61.78, 62.22, 62.87, 97.91, 122.37, 139.68; HRMS (MALDI) calcd. for C16H32O3SiNa 
[M+Na+] 323.2013, found 323.2001. 
(Z)-2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-en-1-ol (34). A solution of 1 
M TBAF in THF (4.36 mL, 4.36 mmol) was added dropwise to solution of 33 (437 mg, 
1.45 mmol) in THF (15 mL) at 0 oC. The temperature was allowed to rise to room 
temperature. After stirring for 3 h, the reaction was quenched with brine (15 mL). The 
layers were separated, and the aqueous layer was extracted with ether (3x10 mL). The 





pressure, the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 315 mg (94%) of 34 as colorless 
oil. Rf 0.25 (hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.52-1.86 (9H, m, 
CH3, 3CH2), 2.59 (1H, s broad, OH), 3.50-3.57 (1H, m, CH), 3.82-3.90 (1H, m, CH), 
4.00-4.27 (4H, s, 2CH2), 4.70 (1H, t, J = 2.9 Hz, CH), 5.51 (1H, t, J = 7.2 Hz, CH); 13C 
NMR (CDCl3, 75 MHz) δ 19.14, 21.85, 25.29, 30.38, 61.42, 61.96, 62.42, 96.98, 123.25, 
141.01; HRMS (MALDI) calcd. for C10H18O3Na [M+Na+] 209.1148, found 209.1158. 
(Z)-2-[2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyl]-isoindole-1,3-dione 
(35). A solution of DIAD (223 mg, 1.1 mmol) in THF (1 mL) was added dropwise via a 
syringe to a solution of an alcohol 34 (187 mg, 1 mmol), phthalimide (162 mg, 1.1 
mmol), and PPh3 (289 mg, 1.1 mmol), in THF (4 mL) at the room temperature.  After 
stirring overnight the solvent was removed at reduced pressure. The residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 25% 
ethyl acetate) to give 241 mg (76%) of 35 as white solid.  Rf 0.63 (hexanes:ethyl acetate  
1:1); mp = 77-78 oC; 1H NMR (CD2Cl2, 300 MHz) δ1.1.48-1.83 (9H, m, CH3, 3CH2), 
3.47-3.54 (1H, m, CH), 3.83-3.91 (1H, m, CH), 4.21-4.28 (1H, m, CH), 4.32 (2H, s, 
CH2), 4.38-4.45 (1H, m, CH),  4.65-4.67 (1H, m, CH), 5.53-5.59 (1H, m, CH), 7.70-7.76 
(2H, m, 2CH), 7.80-7.84 (2H, m, 2CH); 13C NMR (CD2Cl2, 75 MHz) δ 20.13, 21.85, 
26.10, 31.25, 38.76, 62.65, 63.51, 98.55, 123.63, 126.70, 132.62, 134.30, 134.51, 168.66; 
HRMS (MALDI) calcd. for C18H21NO4Na [M+Na+] 338.1363, found 338.1357. 
(Z)-2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enylamine (36). To a 
solution of phthalimide 35 (318 mg, 1 mmol) in EtOH (9 mL) was added hydrazine 





stirred at that temperature for 30 min, then refluxed for 2 h. The solution was cooled, 
filtrated, and the filter cake was washed with EtOH (3x10 mL). The solvent was removed 
at reduced pressure. A residue was redissolved in ether (20 mL). Then 1M NaOH (5 mL) 
was added to adjust the pH to 12. The aqueous layer was saturated with NaCl and 
extracted with ether (3x20 mL). The combined organic extracts were dried over Na2SO4. 
The solvent was removed at reduced pressure to give 144 mg (77%) of 36 as yellow 
liquid. This material was used without further purification. 1H NMR (CD2Cl2, 300 MHz) 
δ1.1.40-1.81 (11H, m, NH2, CH3, 3CH2), 3.23 (2H, s, CH2), 3.44-3.50 (1H, m, CH), 3.78-
3.86 (1H, m, CH), 3.95-4.02 (1H, m, CH), 4.15-4.21 (1H, m, CH),  4.57-4.60 (1H, m, 
CH), 5.34-5.41 (1H, m, CH); 13C NMR (CD2Cl2, 75 MHz) δ 20.09, 22.06, 26.07, 31.23, 
42.91, 62.56, 63.14, 98.18, 122.61, 142.44. 
(Z)-[2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyl]-carbamic acid tert-
butyl ester (37). Amine 36 (600 mg, 3.24 mmol) was dissolved in iPrOH/H2O (3:1, v/v, 
140 mL) and solid Na2CO3 (3.24 g) was added. The solution was cooled to 0 oC. A 
solution of di-tert-butyl dicarbonate (1.46 g, 6.48 mmol) in iPrOH/H2O (3:1, v/v, 20 mL) 
was added. The mixture was stirred overnight at room temperature. iPrOH was removed 
at reduced pressure, and the aqueous layer was extracted with ether (3x30 mL). The 
combined organic extracts were  dried over Na2SO4. The solvent was removed at reduced 
pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate (0% to 15% ethyl acetate) to give 640 mg (69%) of 37 as colorless 
oil. Rf 0.56 (hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.26-1.89 (18H, 
m, 4CH3, 3CH2), 3.49-3.56 (1H, m, CH), 3.78 (2H, d, J = 5.9 Hz, CH2), 3.83-3.90 (1H, 





(1H, s broad, NH), 5.51 (1H, t, J = 7 Hz, CH); 13C NMR (CDCl3, 75 MHz) δ 19.40, 
22.03, 25.34, 28.34, 30.51, 40.81, 62.18, 62.71, 79.12, 97.74, 124.13, 138.00, 155.98; 
HRMS (MALDI) calcd. for C15H27NO4Na [M+Na+] 308.1828, found 308.1828. 
 (Z)-(4-Hydroxy-2-methyl-but-2-enyl)-carbamic acid tert-butyl ester (38). 
PPTS (25 mg, 0.1 mmol) was added to the solution of acetal 37 (286 mg, 1 mmol) in 
EtOH (10 mL). The resulted solution was stirred at 55 oC for 1 h. Then solution was 
cooled down to room temperature. The solvent was removed at reduced pressure, and the 
residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate 
(0% to 40% ethyl acetate) to give 198 mg (98%) of 38 as colorless oil. Rf 0.56 
(hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.43 (9H, s, 3CH3), 1.76 (3H, 
t, J = 0.7 Hz, CH3), 3.19 (1H, broad s, OH), 3.74 (2H, dd, J1 = 5.6 Hz, J2 = 0.7 Hz, CH2), 
4.14 (2H, t, J = 6.5 Hz, CH2), 4.91 (1H, broad s, NH), 5.67 (1H, t, J = 7.3 Hz, CH); 13C 
NMR (CDCl3, 75 MHz) δ 21.62, 28.34, 40.67, 57.53, 79.88, 127.16, 136.24, 156.23; 
HRMS (MALDI) calcd. for C10H19NO3Na [M+Na+] 224.1263, found 224.1268. 
(Z)-[4-(Bis-benzyloxy-phosphoryloxy)-2-methyl-but-2-enyl]-carbamic acid 
tert-butyl ester (39). A solution of I2 (609 mg, 2.4 mmol) in CH2Cl2 (30 mL) was added 
to a solution of P(OBn)3 in CH2Cl2 (20 mL) at -40 oC. The mixture was stirred for 15 min 
and the cold bath was removed. After 30 min the solution became colorless, and then it 
was cannulated to a mixture of alcohol 38 (200 mg, 1.2 mmol) and pyridine (570 mg, 7.2 
mmol) in CH2Cl2 (30 mL) at -40 oC over 30 min period. After the addition was complete, 
the mixture was stirred for 1 h at room temperature. Then the solvents were removed at 
reduced pressure, and the residue was redissolved in ether (50 mL) and washed with 0.3 





extracts were  dried over Na2SO4. The solvent was removed at reduced pressure, and the 
residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate 
(0% to 30% ethyl acetate) to give 320 mg (70%) of 39 as colorless oil. Rf 0.48 
(hexanes:ethyl acetate  1:1); 1H NMR (CDCl3, 300 MHz) δ 1.44 (9H, s, 3CH3), 1.74 (3H, 
t, J = 0.6 Hz, CH3), 3.71 (2H, d, J = 6.2 Hz, CH2), 4.54 (2H, d, J1 = 7.7 Hz, J2 = 2.3 Hz, 
CH2), 4.94 (1H, broad s, NH), 5.02 (2H, dd, J1 = 6.5 Hz, J2 = 1.7 Hz, CH2), 5.43 (1H, t, J 
= 7 Hz, CH), 7.35 (10H, s, 10CH); 13C NMR (CDCl3, 75 MHz) δ 21.80, 28.39, 40.35, 
63.37, 63.44, 69.14, 69.22, 121.83, 121.90, 127.93, 128.01, 128.52, 128.57, 128.69, 
135.77, 135.87, 140.53, 156.09; 31P NMR (CDCl3, 125 MHz) δ 0.68; HRMS (MALDI) 
calcd. for C24H32NO6PNa [M+Na+] 484.1865, found 484.1872. 
[4-(Bis-benzyloxy-phosphoryloxy)-2R,3S-dihydroxy-2-methyl-butyl]-
carbamic acid tert-butyl ester (40). Olefine 39 (250 mg, 0.56 mmol) was 
asymmetrically dihydroxylated following the general Sharpless procedure. The residue 
was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 
30% ethyl acetate) to give 172 mg (64%) of 40 as colorless oil. Rf 0.25 (hexanes:ethyl 
acetate 1:1); [α]D20 + 11.7 (c 0.75, CHCl3);  1H NMR (CDCl3, 300 MHz) δ .04 (3H, s, 
CH3), 1.43 (9H, s, 3CH3), 2.96-3.05 (2H, m, 2CH), 3.33-3.40 (1H, m, CH), 3.68-3.72 
(1H, m, CH), 3.98-4.07 (1H, m, CH), 4.33 (1H, t, J = 10.5 Hz, CH), 4.69 (2H, s, CH2), 
4.98-5.09 (4H, m, 2CH2), 5.36 (1H, broad s, NH), 7.34 (10H, s, 10CH); 13C NMR 
(CDCl3, 75 MHz) δ 19.67, 28.30, 48.40, 69.30, 69.37, 69.59, 69.67, 73.27, 73.80, 80.36, 
128.05, 128.08, 128.62 135.52, 135.61, 158.32; 31P NMR (CDCl3, 125 MHz) δ 0.72; 






Phosphoric acid mono-(4-amino-2R,3S-dihydroxy-3-methyl-butyl) ester (42). 
Ester 41 (100 mg, 0.2 mmol) was dissolved in CH3OH (5 mL), flushed with H2, and Pd/C 
(8 mg) was added. The reaction was stirred for 1 h under a balloon of H2 gas. The 
mixture was concentrated at reduced pressure. A 1H NMR spectrum showed that no 
benzyl groups remained. The residue was redissolved in CH3OH (4 mL) and 3 M HCl (1 
mL) was added. After 30 min the mixture was concentrated at reduced pressure, and 
chromatographed on silica eluted with iPrOH:H2O:NH4OH (6:0.5:2.5 v/v/v) mixture to 
give 41 mg (89%) of 42 as white solid. Rf 0.38 (iPrOH:H2O:NH4OH (6:1:3 v/v/v)); [α]D20 
+ 15.4 (c 0.65, D2O); 1H NMR (D2O, 300 MHz) δ 1.26 (3H, s, CH3), 3.07 (1H, d, J = 
13.2 Hz, CH), 3.25 (1H, d, J = 13.2 Hz, CH), 3.75-3.77 (1H, m, CH), 3.81-3.91 (1H, m, 
CH), 3.97-4.04 (1H, m, CH); 13C NMR (D2O, 75 MHz) δ 20.39, 46.23, 64.51, 71.39, 
75.78 (J = 7 Hz); 31P NMR (D2O, 125 MHz) δ 4.20; HRMS (MALDI) calcd. for 
C5H13NO6P [M-H] 214.0486, found 214.0489. 
4-(tert-Butyl-dimethyl-silanyloxy)-2S,3S-dihydroxy-3-methyl-butyric acid 
methyl ester (43). Olefine 27 (300 mg, 1.16 mmol) was asymmetrically dihydroxylated 
following the general Sharpless procedure. The residue was chromatographed on silica 
with gradient elution by hexanes/ethyl acetate (0% to 15% ethyl acetate) to give 250 mg 
(73%) of 43 as colorless oil. Rf 0.14 (hexanes:ethyl acetate  4:1); er 18/1 (by 19F NMR 
analysis of the Mosher ester); [α]D20 + 26.2 (c 1.8, CHCl3); 1H NMR (CDCl3, 300 MHz) 
δ 0.09 (6H, s, 2CH3), 0.91 (9H, s, 3CH3), 1.17 (3H, d, J = 0.6 Hz, CH3), 3.10 (1H, s, OH), 
3.34-3.37 (1H, m, OH), 3.48 (1H, d, J = 10 Hz, CH), 3.68 (1H, d, J = 10 Hz, CH), 3.81 





18.25, 19.64, 25.78, 52.45, 67.98, 73.26, 74.95, 173.65; HRMS (MALDI) calcd. for 
C12H26O5SiNa [M+Na+] 301.1435, found 301.1435. 
5-(tert-Butyl-dimethyl-silanyloxymethyl)-2S-methoxy-5-methyl-
[1,3S]dioxolane-4-carboxylic acid methyl ester (44). To diol 43 (200 mg, 0.69 mmol) 
in CH2Cl2 (8mL) was added trimethyl orthoformate (291 mg, 2.74 mmol) in CH2Cl2 (1 
mL) and CSA (16 mg, 0.07 mmol) in CH2Cl2 (1 mL). After stirring overnight, the 
solution was washed with saturated NaHCO3. The layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3x20 mL). The combined organic extracts were dried 
over Na2SO4. The solvent was removed at reduced pressure to give 230 mg (quant) of 44 
as colorless oil. This material was unstable on silica column and was used without 
purification. Rf 0.63 (hexanes:ethyl acetate 3:2); dr 87/13 (by 1H NMR analysis of the 
orthoester); for major diastereomer 1H NMR (CDCl3, 300 MHz) δ 0.02 (6H, s, 2CH3), 
0.86 (9H, s, 3CH3), 1.49 (3H, s, CH3), 3.34 (3H, s, CH3), 3.56 (2H, dd, J1 = 18 Hz, J2 = 
10.6 Hz, CH2), 4.40 (1H, s, CH), 5.88 (1H, s, CH); 13C NMR (CDCl3, 75 MHz) δ -5.66, -
5.55, 18.25, 22.43, 25.72, 51.56, 52.13, 65.56, 79.04, 84.66, 115.95, 168.47; HRMS 
(MALDI) calcd. for C14H28O6SiNa [M+Na+] 343.1547, found 343.1558.  
[5-(tert-Butyl-dimethyl-silanyloxymethyl)-2R-methoxy-5-methyl-
[1,3S]dioxolan-4-yl]-methanol (45). A solution of 2 M LiBH4 in THF (0.6 mL, 1.2 
mmol) was added dropwise by a syringe to a solution of 44 (200 mg, 0.6 mmol) in ether 
(20 mL) at room temperature. The resulting solution was stirred for 1 h at the same 
temperature. After addition of EtOH (5 mL) and brine (5 mL), the organic layer was 
separated, and the aqueous layer was extracted ether (3x10 mL). The combined organic 





175 mg (quant) of 45 as colorless oil. This material was unstable on silica column and 
was used without purification. Rf 0.63 (hexanes:ethyl acetate 3:2); dr 87/13 (by 1H NMR 
analysis of the orthoester); for major diastereomer 1H NMR (CDCl3, 300 MHz) δ 0.11 
(6H, s, 2CH3), 0.91 (9H, s, 3CH3), 1.45 (3H, s, CH3), 3.32 (3H, s, CH3), 3.71-4.09 (5H, 
m, CH, 2CH2), 5.67 (1H, s, CH);  13C NMR (CDCl3, 75 MHz) δ  -5.72, -5.70, 18.07, 
22.79, 25.68, 51.72, 60.33, 64.95, 81.26, 82.63, 114.79; HRMS (FTMS) calcd. for 
C12H25O4Si [M-OCH3] 261.1517, found 261.15164. 
Toluene-4-sulfonic acid 5-(tert-butyl-dimethyl-silanyloxymethyl)-2R-
methoxy-5-methyl-[1,3S]dioxolan-4-ylmethyl ester (46). Alcohol 45 (60 mg, 0.21 
mmol) and DMAP (75 mg, 0.62 mmol) were dissolved in CH2Cl2 (5 mL). To the solution 
was added p-TsCl (78 mg, 0.41 mmol) in CH2Cl2 (2 mL) via syringe. The mixture was 
allowed to stir overnight. The solvents were removed at reduced pressure, and the residue 
was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 
10% ethyl acetate) to give 90 mg (98%) of 46 as colorless oil. Rf 0.59 (hexanes:ethyl 
acetate  3:2); dr 87/13 (by 1H NMR analysis of the orthoester); [α]D20 + 10.2 (c 0.9, 
CHCl3); for major diastereomer 1H NMR (CDCl3, 300 MHz) δ 0.82 (9H, s, 3CH3), 1.34 
(3H, s, CH3), 2.45 (3H, s, CH3), 3.29 (3H, s, CH3), 3.32 (1H, d, J = 10.5 Hz, CH), 3.50 
(1H, d, J = 10.5 Hz, CH), 4.10-4.18 (2H, m, CH2), 4.33-4.41 (1H, m, CH), 5.68 (1H, s, 
CH), 7.13 (2H, d, J = 8 Hz, 2CH), 7.80 (2H, d, J = 8.3 Hz, 2CH); 13C NMR (CDCl3, 75 
MHz) δ -5.85, -5.74, 17.88, 21.59, 25.63, 51.45, 65.08, 68.35, 79.73, 82.52, 115.35, 
128.00, 129.86, 132.74, 144.89; HRMS (FTMS) calcd. for C19H31O6SSi [M-OCH3] 






3-methyl-butyl ester (48). To 46 (230 mg, 0.54 mmol) was added HCl in THF (6 mL, 
3M HCl:THF, 1:25). After stirring for 30 min, the solution was cooled to 0 oC and 6 mL 
of half saturated ammonia in MeOH were added. The solution was stirred for 15 min at 
room temperature. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% 
ethyl acetate) to give 160 mg (76%) of 48 as colorless oil. Rf 0.36 (hexanes:ethyl acetate 
1:1); [α]D20 + 18.9 (c 1.7, CHCl3);  1H NMR (CDCl3, 300 MHz) δ 0.06 (6H, s, 2CH3), 
0.88 (9H, s, 3CH3), 1.07 (3H, s, CH3), 2.45 (3H, d, J = 0.3 Hz, CH3), 2.71-2.74 (2H, 
broad, 2OH), 3.38 (1H, d, J = 9.8 Hz, CH), 3.67 (1H, d, J = 9.8 Hz, CH), 3.82 (1H, dd, J1 
= 5.8 Hz, J2 = 2.5 Hz, CH), 4.09 (1H, dd, J1 = 8.2 Hz, J2 = 2.0 Hz, CH), 4.32 (1H, dd, J1 = 
8.0 Hz, J2 = 2.5 Hz, CH), 7.36 (2H, d, J = 8 Hz, 2CH), 7.81 (2H, d, J = 8.2 Hz, 2CH); 13C 
NMR (CDCl3, 75 MHz) δ -5.62, 18.13, 18.99, 21.63, 25.77, 67.55, 71.99, 72.65, 72.94, 
127.97, 129.92, 132.60, 145.00; HRMS (FTMS) calcd. for C18H33O6SSi [M+H+] 
405.17616, found 405.17603. 
1-(tert-Butyl-dimethyl-silanyloxy)-2-oxiranyl-propan-2-ol (49). To diol 48 
(367 mg, 0.91 mmol) in THF (6 mL) at 0 oC was added tBuOK (112 mg, 1.0 mmol) in 
THF (4 mL). The solution was stirred for 1 h at 0 oC. The solvent was removed at 
reduced pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate to give 196 mg (93%) of 49 as colorless oil. Rf 0.36 (hexanes:ethyl 
acetate 1:1); [α]D20 + 15.0 (c 2.6, CHCl3);  1H NMR (CDCl3, 300 MHz) δ 0.08 (6H, s, 
2CH3), 0.91 (9H, s, 3CH3), 1.18 (3H, s, CH3), 2.36 (1H, s, OH), 2.74 (1H, dd, J1 = 4.0 





Hz, J2 = 1.2 Hz, CH), 3.51 (1H, d, J = 9.8 Hz, CH), 3.61 (1H, d, J = 9.8 Hz, CH); 13C 
NMR (CDCl3, 75 MHz) δ -5.56, 18.20, 20.92, 25.78, 44.04, 55.68, 68.42, 70.23; HRMS 
(FTMS) calcd. for C11H25O3Si [M+H+] 233.15675, found 233.15712. 
2-Oxiranyl-propane-1,2-diol (50). Et3N-3HF complex (1.1 g, 6.9 mmol) in THF 
(2 mL) was added dropwise to a solution of silyl ether 49 (160 mg, 0.69 mmol) in THF (8 
mL) at room temperature. After stirring overnight, Et3N (10 mL) was added. The solvent 
was removed at reduced pressure, and the residue was chromatographed on silica with 
gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 68 mg (83%) 
of 50 as colorless oil. Rf 0.29 (hexanes:ethyl acetate  1:1); er 17/1 (by 19F NMR analysis 
of the Mosher ester); [α]D20 + 17.4 (c 0.65, CHCl3);  1H NMR (CDCl3, 300 MHz) δ 1.26 
(3H, s, CH3), 2.36 (1H, m, OH), 2.50 (1H, s, OH), 2.81-2.88 (2H, m, CH2), 3.04 (1H, dd, 
J1 = 2.9 Hz, J2 = 1.1 Hz, CH), 3.49-3.62 (2H, m, CH2); 13C NMR (CDCl3, 75 MHz) δ 
22.28, 44.49, 56.55, 67.21, 70.29;  HRMS (FTMS) calcd. for C5H9O2 [M-OH] 
101.05971, found 101.06000. 
Thiophosphoric acid S-(2,3,4-trihydroxy-3-methyl-butyl) ester (51). To 
epoxide 50 (34 mg, 0.29 mmol) was added trisodium thiophosphate (126 mg, 0.32 mmol) 
in H2O (0.6 mL) at room temperature. The solution was stirred overnight. After that the 
mixture was lyophilized and the residue was chromatographed on cellulose column 
eluted with (50 mM NH4HCO3 iPrOH:H2O) using gradient method  (iPrOH:H2O from 
8:2 to 7:3 v/v) to give 25 mg of 51 (32%).  Rf. 0.42 (iPrOH:H2O:NH4OH 6/1/3 v/v/v) 
[α]D20 + 16.3 (c 0.53, D2O); 1H NMR (D2O, 300 MHz) δ 1.09 (3H, s, CH3), 2.67-2.78 
(1H, m, CH), 2.96-3.05 (1H, m, CH), 3.51 (2H, dd, J1 = 17.2 Hz, J2 = 11.8 Hz, CH2), 3.72 





Hz), 66.70, 75.02, 75.48 (J = 3 Hz); 31P NMR (D2O, 125 MHz) δ 17.82; HRMS (FTMS) 
calcd. for C5H14O6PS [M+H+] 233.02432, found 233.02482. 
tert-Butyl(3-methylbut-2-enyloxy)diphenylsilane (52). To the mixture of the 3-
methylbut-2-en-1-ol (15 g, 172.4 mmol) and DMAP (32 g, 258.6 mmol) in CH2Cl2 (300 
mL) was added a solution of TBDPSCl (53.2 g, 275 mmol) in CH2Cl2 (200 mL) via 
cannula in 30 min at room temperature. The resulting mixture was stirred overnight, 
transferred into a separation funnel containing brine (500 mL), and extracted with CH2Cl2 
(3x100 mL). The combined extracts were dried over Na2SO4. The solvent was removed 
at reduced pressure, and the residue was chromatographed on silica with gradient elution 
by hexanes/ethyl acetate (0% to 5% ethyl acetate) to give 52 g (92%) of 52 as colorless 
oil. Rf 0.63 (hexanes:ethyl acetate 7:3); 1H NMR (CDCl3, 300 MHz) δ 1.05 (9H, s, 
3CH3), 1.45 (3H, s, CH3), 1.69 (3H, J = 1 Hz, CH3), 4.20 (2H, dt, J1 = 6.5 Hz, J2 = 1 Hz, 
CH2), 5.35-5.41 (1H, m, CH), 7.34-7.43 (6H, m, 6CH), 7.68-7.72 (4H, m, 4CH); 13C 
NMR (CDCl3, 75 MHz) δ 17.91, 19.16, 25.70, 26.83, 61.10, 124.18, 127.56, 129.47, 
133.77, 134.03, 135.59; HRMS (FTMS) calcd. for C21H28OSiNa [M+Na+] 347.18016, 
found 347.18007. 
(E)-4-(tert-Butyldiphenylsilyloxy)-2-methylbut-2-enal (53) and (E)-4-(tert-
butyldiphenylsilyloxy)-2-methylbut-2-en-1-ol (54). To a solution of 52 (25.81 g, 79.53 
mmol) in CH2Cl2 (100 mL) was added TBHP (30 mL, 90% solution in water), selenious 
acid (1 g), and salicylic acid (1 g). The mixture was stirred for 17 h at room temperature. 
The solution was transferred into a separation funnel containing water (200 mL) and was 
extracted with ether (3x50 mL). The combined extracts were dried over Na2SO4. The 





pressure by co-evaporation with toluene (3x100 mL). The residue was chromatographed 
on silica with gradient elution by hexanes/ethyl acetate (0% to 25% ethyl acetate) to give 
16.4 g (61%) of aldehyde 53 as colorless oil. Rf 0.5 (hexanes:ethyl acetate 7:3); 1H NMR 
(CDCl3, 300 MHz) δ 1.05 (9H, s, 3CH3) 1.56 (3H, dd, J1 = 2.5 Hz, J2 = 1.2 Hz, CH3), 
4.56 (2H, dq, J1 = 5.3 Hz, J1 = 1 Hz, CH2), 6.59-6.65 (1H, m, CH), 7.39-7.48 (6H, m, 
6CH), 7.70-7.74 (4H, m, 4CH), 9.43 (1H, s, CH); 13C NMR (CDCl3, 75 MHz) δ 9.22, 
19.06, 26.66, 61.20, 127.64, 127.80, 129.87, 132.89, 135.44, 137.80, 152.41, 194.46; 
HRMS (FTMS) calcd. for C21H27O2Si [M+H+] 339.17748, found 339.17740. and 8.4 g 
(31%) of alcohol 54 as colorless oil. Rf 0.25 (hexanes:ethyl acetate 7:3); 1H NMR 
(CDCl3, 300 MHz) δ 1.05 (9H, s, 3CH3), 1.41 (1H, s broad, OH), 1.48 (3H, s, CH3), 3.95 
(2H, d, J = 4.7 Hz, CH2), 4.27 (2H, dd, J1 = 6.2 Hz, J2 = 1 Hz, CH2), 5.59-5.65 (1H, m, 
CH), 7.35-7.46 (6H, m, 6CH), 7.67-7.71 (4H, m, 4CH); 13C NMR (CDCl3, 75 MHz) δ 
13.73, 19.11, 26.78, 60.72, 68.18, 124.84, 127.61, 129.57, 133.79, 135.57, 136.13; 
HRMS (MALDI) calcd. for C21H28O2SiNa [M+Na+] 363.1751, found 363.1741. 
(E)-4-(tert-Butyldiphenylsilyloxy)-2-methylbut-2-en-1-ol (54). To a solution of 
aldehyde 53 (14.84 g, 43.84 mmol) in EtOH (200 mL) at 0 oC was added NaBH4 (6.6 g, 
175.4 mmol) in small portions during 15 min. The mixture was stirred for 2 h at room 
temperature. The solvent was removed at reduced pressure. The residue was portioned 
between ether (100 mL) and water (400 mL). The aqueous layer was extracted with ether 
(3x100 mL). The combined organic layers were washed with brine (100 mL), and dried 
over Na2SO4. After evaporation of the solvents, the residue was chromatographed on 
silica with gradient elution by hexanes/ethyl acetate (0% to 25% ethyl acetate) to give 





300 MHz) δ 1.05 (9H, s, 3CH3), 1.41 (1H, s broad, OH), 1.48 (3H, s, CH3), 3.95 (2H, d, J 
= 4.7 Hz, CH2), 4.27 (2H, dd, J1 = 6.2 Hz, J2 = 1 Hz, CH2), 5.59-5.65 (1H, m, CH), 7.35-
7.46 (6H, m, 6CH), 7.67-7.71 (4H, m, 4CH); 13C NMR (CDCl3, 75 MHz) δ 13.73, 19.11, 
26.78, 60.72, 68.18, 124.84, 127.61, 129.57, 133.79, 135.57, 136.13; HRMS (MALDI) 
calcd. for C21H28O2SiNa [M+Na+] 363.1741, found 363.1751. 
((2R,3R)-3-((tert-Butyldiphenylsilyloxy)methyl)-2-methyloxiran-2-yl) 
methanol (55). An oven dried 250 mL round-bottomed flask equipped with a magnetic 
stirring bar was charged with 3.0 g of 4Å molecular sieves and CH2Cl2 (100 mL). The 
mixture was cooled to -30 oC and D-(-)-diethyl tartrate (1.8 g, 8.46 mmol) and Ti(OiPr)4, 
(2 g, 7.05 mmol, via) were added with stirring. The reaction mixture was stirred at -30 oC 
as TBHP (9.4 mL, 47 mmol, 5-6 M in dodecane) was added by syringe. The resulting 
mixture was stirred at -30 oC for 30 min. Alcohol 54 (8 g, 23.5 mmol) in CH2Cl2 (50 
mL), was added dropwise via cannula over 20 min. The mixture was stirred for 5 h at -20 
to -15 oC. The cold bath was removed and a 10% NaOH solution in brine (20 mL) was 
added. The mixture was allowed to stir for additional 30 min., before the contents of the 
flask were transferred to a separation funnel and organic layer was removed. The aqueous 
layer was extracted with ether (3x20 mL). The combined organic layers were dried over 
Na2SO4. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% 
ethyl acetate) to give 7.95 g (95%) of 55 as colorless oil. Rf 0.23 (hexanes:ethyl acetate 
7:3); er 12/1 (by 19F NMR analysis of the Mosher ester); [α]D20 + 10.8 (c 0.9, CHCl3); 1H 
NMR (CDCl3, 300 MHz) δ 1.06 (9H, s, 3CH3), 1.12 (3H, s, CH3), 2.07 (1H, dd, J1 = 8.4 





m, CH2), 7.38-7.49 (6H, m, 6CH), 7.69-7.77 (4H, m, 4CH); 13C NMR (CDCl3, 75 MHz) 
δ 14.08, 19.13, 26.68, 59.68, 60.68, 62.39, 65.01, 127.71, 129.75, 133.03, 133.27, 135.49, 
135.53; HRMS (MALDI) calcd. for C21H28O3SiNa [M+Na+] 379.1700, found 379.1710. 
(((2R,3S)-3-(Bromomethyl)-3-methyloxiran-2-yl)methoxy)(tert-butyl) 
diphenylsilane (56). To a solution of epoxy alcohol 55 (1.5 g, 4.2 mmol) and CBr4 (1.7 
g, 5.0 mmol) in CH2Cl2 (40 mL) at 0 oC was added a solution of PPh3 (1.45 g, 5.46 
mmol) in CH2Cl2 (20 mL). The resulting solution was stirred at 0 oC for 2 h and diluted 
with ether (60 mL), and the white precipitate was removed by filtration. The solvent was 
removed at reduced pressure, and the residue was chromatographed on silica with 
gradient elution by hexanes/ethyl acetate (0% to 10% ethyl acetate) to give 1.5 g (85%) 
of 56 as colorless oil. Rf 0.69 (hexanes:ethyl acetate 4:1); [α]D20 - 0.5 (c 0.785, CHCl3);  
1H NMR (CDCl3, 300 MHz) δ 1.07 (9H, s, 3CH3), 1.29 (3H, s, CH3), 3.15 (1H, t, J =5.4 
Hz, CH), 3.30 (2H, dd, J1 = 30 Hz, J2 =  10 Hz, CH2), 3.73-3.85 (2H, m, CH2), 7.36-7.46 
(6H, m, 6CH), 7.67-7.70 (4H, m, 4CH); 13C NMR (CDCl3, 75 MHz) δ 15.15, 19.15, 
2.69, 39.12, 59.29, 62.43, 64.23, 127.76, 129.82, 132.96, 133.18, 135.51 135.54; HRMS 
(MALDI) calcd. for C21H27BrO2SiNa [M+Na+] 441.0856, found 441.0858. 
(S)-((2S,3R)-3-((tert-Butyldiphenylsilyloxy)methyl)-2-methyloxiran-2-yl) 
methyl ethanethioate (57). To a solution of KSAc (826 mg, 7.24 mmol) in DMF (40 
mL) was added via cannula a solution of epoxy bromide 56 (1.5 g, 3.62 mmol) in DMF 
(20 mL) at room temperature. The solution was stirred overnight at room temperature, 
and transferred to a separation funnel containing water (600 mL) and ether (100 mL). The 
aqueous layer was extracted with ether (3x100 mL). The combined organic layers were 





chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 10% 
ethyl acetate) to give 1.17 g (79%) of 57 as colorless oil. Rf 0.68 (hexanes:ethyl acetate 
4:1); [α]D20 + 15.4 (c 0.8, CHCl3); 1H NMR (CDCl3, 300 MHz) δ 1.06 (9H, s, 3CH3), 
1.15 (3H, s, CH3), 2.36 (3H, s, CH3), 3.08 (2H, d, J = 14 Hz, CH2), 3.13 (1H, t, J = 5.4 
Hz, CH), 3.69-3.82 (2H, m, CH2), 7.36-7.46 (6H, m, 6CH), 7.66-7.70 (4H, m, 4CH); 13C 
NMR (CDCl3, 75 MHz) δ 16.02, 19.15, 26.68, 30.42, 36.67, 59.26, 62.40, 62.85, 127.73, 
129.77, 133.04, 133.27, 135.51, 135.54, 194.51; HRMS (MALDI) calcd. for 
C23H30O3SSiNa [M+Na+] 437.1577, found 437.1578. 
(R)-2-(tert-Butyldiphenylsilyloxy)-1-((R)-2-methylthiiran-2-yl)ethanol (58). 
To the solution of thioacetate 57 (1.17 g, 2.82 mmol) in MeOH (20 mL) at -30 oC was 
added MeONa (25% wt, 153 mg, 0.71 mmol) in MeOH (10 mL) via syringe. The mixture 
was left overnight in the freezer at -20 oC without stirring. The reaction mixture was 
quenched with saturated solution of NH4Cl (10 mL). The solvent was removed at reduced 
pressure, and the mixture was redissolved in ether (100 mL) and water (100 mL). The 
aqueous layer was extracted with ether (3x20 mL). The combined organic layers were 
dried over Na2SO4. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 15% 
ethyl acetate) to give 1.17 g (95%) of 58 as colorless oil. Rf 0.6 (hexanes:ethyl acetate 
4:1); er 10/1 (by 19F NMR analysis of the Mosher ester); [α]D20 + 5.5 (c 1.26, CHCl3); 1H 
NMR (CDCl3, 300 MHz) δ 1.07 (9H, s, 3CH3), 1.57 (3H, s, CH3), 2.34 (1H, d, J = 1.2 
Hz, CH), 2.60 (1H, d, J = 1.1 Hz, CH), 2.75 (1H, d, J = 2.6 Hz, CH), 3.52-3.56 (1H, m, 
CH), 3.78-3.89 (2H, m, CH2), 7.36-7.48 (6H, m, 6CH), 7.65-7.71 (4H, m, 4CH); 13C 





127.79, 129.83, 132.82, 132.98, 135.53, 135.55; HRMS (MALDI) calcd. for 
C21H28O2SSiNa [M+Na+] 395.1472, found 395.1456. 
(R)-2-(tert-Butyldiphenylsilyloxy)-1-((R)-2-methylthiiran-2-yl)ethyl acetate 
(59). To a solution of alcohol 58 (1 g, 2.68 mmol) and DMAP (530 mg, 4.29 mmol) in 
CH2Cl2 (20 mL) was added a solution of AcCl (228 µL, 3.22 mmol) in CH2Cl2 (5 mL) by 
syringe over 15 min at room temperature. The solution was stirred overnight, and washed 
with water (20 mL). The aqueous layer was extracted with ether (3x10 mL). The 
combined organic layers were dried over Na2SO4. The solvent was removed at reduced 
pressure, and the residue was chromatographed on silica with gradient elution by 
hexanes/ethyl acetate (0% to 10% ethyl acetate) to give 1.01 g (91%) of 58 as colorless 
oil. Rf 0.69 (hexanes:ethyl acetate 4:1); [α]D20 + 2.7 (c 1.44, CHCl3);  1H NMR (CDCl3, 
300 MHz) δ 1.04 (9H, s, 3CH3), 1.51 (3H, s, CH3), 2.07 (3H, s, CH3), 2.25 (1H, d, J = 1.1 
Hz, CH), 2.59 (1H, d, J = 1 Hz, CH), 3.88-3.96 (2H, m, CH2), 4.77 (1H, dd, J1 =  4.4 Hz, 
J2 = 2 Hz, CH), 7.36-7.47 (6H, m, 6CH), 7.65-7.69 (4H, m, 4CH); 13C NMR (CDCl3, 75 
MHz) δ 19.13, 21.06, 21.65, 26.63, 32.87, 42.14, 64.28, 79.41, 127.70, 127.72, 129.72, 
129.79, 133.02, 133.23, 135.53, 135.61, 170.22; HRMS (FTMS) calcd. for 
C23H30O3SSiNa [M+Na+] 437.15765, found 437.15771. 
(2S,3R)-2-(Acetylthio)-4-(tert-butyldiphenylsilyloxy)-2-methylbutane-1,3-diyl 
diacetate (60). Thiirane 59 (4g, 9.65 mmol) was dissolved in acetic anhydride (250 mL) 
and acetic acid (250 mL). To the resulting mixture was added AcOK (47.3 g, 482.5 
mmol). The mixture was heated at 140 oC for 12 h. Acetic acid and acetic anhydride were 
removed at reduced pressure with co-evaporation with toluene (3x200 mL). The residue 





organic layers were dried over Na2SO4. The solvent was removed at reduced pressure, 
and the residue was chromatographed on silica with gradient elution by hexanes/ethyl 
acetate (0% to 25% ethyl acetate) to give 1.55 g (31%) of 60 as colorless oil. Rf 0.59 
(hexanes:ethyl acetate 1:1); [α]D20 + 1.4 (c 1.75, CHCl3);  1H NMR (CDCl3, 300 MHz) δ 
1.02 (9H, s, 3CH3), 1.51 (3H, s, CH3), 2.00 (3H, s, CH3), 2.09 (3H, s, CH3), 2.21 (3H, s, 
CH3), 3.77-3.91 (2H, m, CH2), 4.39 (2H, q, J = 10.4 Hz, CH2), 5.55 (1H, dd, J1 =  4 Hz, J2 
= 3.4 Hz, CH), 7.36-7.47 (6H, m, 6CH), 7.63-7.68 (4H, m, 4CH); 13C NMR (CDCl3, 75 
MHz) δ 18.73, 19.05, 20.75, 20.91, 26.57, 31.32, 54.90, 62.81, 65.47, 74.39, 127.73, 
129.75, 129.81, 132.84, 133.04, 135.50, 135.62, 169.74, 170.42, 194.56; HRMS (FTMS) 
calcd. for C27H36O6SSiNa [M+Na+] 539.1900, found 539.18958. 
(2S,3R)-4-(tert-Butyldiphenylsilyloxy)-2-methyl-2-(pyridin-2-
yldisulfanyl)butane-1,3-diol (61). To a solution of triacetate 60 (280 mg, 0.54 mmol) 
and 2,2’-pyridyl disulfide (358 mg, 1.63 mmol) in MeOH (10 mL) at -30 oC was added 
MeONa (25% wt, 90 mg, 0.41 mmol) in MeOH (1 mL) via syringe. The mixture was left 
overnight in freezer at -20 oC without stirring, and then quenched with a saturated 
solution of NH4Cl (2 mL). The solvent was removed at reduced pressure, and the mixture 
was diluted with water (20 mL), ether (20 mL) and transferred to a separation funnel. The 
aqueous layer was extracted with ether (3x20 mL). The combined organic layers were 
dried over Na2SO4. The solvent was removed at reduced pressure, and the residue was 
chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 25% 
ethyl acetate) to give 240 mg (89%) of 61 as colorless oil. Rf 0.2 (hexanes:ethyl acetate 
4:1); [α]D20 + 60.8 (c 1.0, CHCl3); 1H NMR (CDCl3, 300 MHz) δ 1.07 (9H, s, 3CH3), 





m, CH), 4.21 (1H, d, J = 4.7, CH), 5.99 (1H, t, J =  7.4 Hz, CH), 7.12-7.16 (1H, m, CH), 
7.33-7.71 (12H, m, 12CH), 8.45-8.47 (1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ 18.06, 
19.17, 26.78, 59.09, 64.75, 65.21, 74.93, 121.58, 122.05, 127.78, 129.81, 132.82, 132.97, 
135.53, 135.61, 136.88, 149.67, 158.78; HRMS (MALDI) calcd. for C26H34NO3S2Si 
[M+H+] 500.1744, found 500.1758. 
(2S,3R)-4-(tert-Butyldiphenylsilyloxy)-2-methyl-2-(pyridin-2-yldisulfanyl) 
butane-1,3-diyl diacetate (62). To a solution of diol 61 (260 mg, 0.52 mmol) and DMAP 
(225 mg, 1.82 mmol) in CH2Cl2 (10 mL) was added a solution of AcCl (93 µL, 1.3 
mmol) in CH2Cl2 (1 mL) by syringe at room temperature. The solution was stirred 
overnight, and washed with water (20 mL). The aqueous layer was extracted with ether 
(3x10 mL). The combined organic extracts were dried over Na2SO4. After the solvent 
was removed at reduced pressure, the residue was chromatographed on silica with 
gradient elution by hexanes/ethyl acetate (0% to 15% ethyl acetate) to give 280 mg (92%) 
of 62 as colorless oil. Rf 0.69 (hexanes:ethyl acetate 4:1); [α]D20 + 26.1 (c 1.4, CHCl3);  1H 
NMR (CDCl3, 300 MHz) δ 1.03 (9H, s, 3CH3), 1.27 (3H, s, CH3), 1.92 (3H, s, CH3), 2.06 
(3H, s, CH3), 3.87 (1H, dd, J1 = 7.4 Hz, J2 = 3.9 Hz, CH), 4.04 (1H, dd, J1 = 8.1 Hz, J2 = 
3.3 Hz, CH), 4.16 (2H, dd, J1 = 23.8 Hz, J2 = 11.8 Hz, CH2), 5.42 (1H, dd, J1 =  4.3 Hz, J2 
= 3.3 Hz, CH), 7.04-7.08 (1H, m, CH), 7.37-7.70 (12H, m, 12CH), 8.39-8.41 (1H, m, 
CH); 13C NMR (CDCl3, 75 MHz) δ 18.55, 19.05, 20.64, 20.90, 26.58, 54.84, 62.74, 
66.74, 75.08, 120.14, 120.89, 127.74, 127.77, 129.76, 129.84, 132.85, 133.00, 135.51, 
135.61, 136.80, 149.42, 160.05, 169.70, 170.34; HRMS (MALDI) calcd. for 






diacetate (63). To a solution of silyl ether 62 (200 mg, 0.34 mol) in THF (5 mL) was 
added 1 M solution TBAF in THF (1 mL, 1 mmol) at room temperature. After stirring for 
2 h at room temperature the solution was concentrated at reduced pressure, and the 
residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate 
(0% to 40% ethyl acetate) to give 280 mg (92%) of 62 as colorless oil. Rf 0.69 
(hexanes:ethyl acetate 4:1); [α]D20 + 62.3 (c 1.00, CHCl3);  1H NMR (CDCl3, 300 MHz) δ 
1.44 (3H, s, CH3), 1.62 (1H, broad s, OH), 2.07 (3H, s, CH3), 2.10 (3H, s, CH3), 3.86 
(1H, m, CH), 4.15 (1H, dd, J1 = 7.8 Hz, J2 = 3.7 Hz, CH), 4.38-4.44 (3H, m, CH, CH2), 
6.32 (1H, d, J = 5.2 Hz, CH) 7.16-7.20 (1H, m, CH), 7.42-7.45 (1H, m, CH), 7.58-7.64 
(1H, m, CH) 8.49-8.52 (1H, m, CH); 13C NMR (CDCl3, 75 MHz) δ 20.69, 20.82, 21.02, 
58.11, 65.22, 65.73, 72.44, 121.77, 122.06, 137.08, 149.72, 158.53, 170.56, 171.09; 
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